

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this

date: Dec. 22, 1999

By: Kinder Barclay Express Mail No.: EL497409366US

**GASTRIC RETENTION DOSAGE FORM HAVING MULTIPLE LAYERS**

This application claims the priority of provisional application No. 60/113,560, filed December 23, 1998.

**FIELD OF THE INVENTION**

The present invention is related to the prolonged release of an active agent from a dosage form. More particularly, it relates to a multilayered active agent dosage form having a highly swellable layer and a drug layer, the dosage form being adapted for retention in the stomach for a prolonged period.

**BACKGROUND OF THE INVENTION**

Controlled release dosage forms that provide for prolonged delivery of active agent formulations to the environment of use have found application for increasing numbers of active agents. However, with respect to pharmaceutical and veterinary active agent formulations, there has been a need not only to provide for prolonged delivery of the active agent over time, but also to provide prolonged delivery of the active agent at a particular location or locations in the environment of use, such as in the stomach.

Certain active agents are absorbed primarily from the small intestine. Generally, the time of passage of different particles through the small intestine does not vary significantly, and passage is generally independent of food intake and particle size. Thus, active agent dissolved in liquid, solid active agent dispersed in liquid and relatively larger delivery units of active agent, such as microcapsules and the like, will traverse the length of the small intestine in substantially the same time frame, usually about 3-5 hours. For active agents that are not easily absorbed by the small intestine or that do not

1 dissolve readily, the window for active agent absorption in the small intestine  
2 may be too short to provide a desired therapeutic effect. This fact often  
3 creates a need for frequent dosing of active agent in order to provide and  
4 maintain adequate levels of active agent in blood plasma. The need for  
5 frequent dosing presents compliance problems and is often inconvenient for  
6 the user as well.

7         Since it has been found difficult to alter the transit time of active agent  
8 through the small intestine, some emphasis has been placed on attempting to  
9 control the transit time of active agents in the stomach. Most active agents  
10 are not well absorbed in the stomach, but even in those instances where the  
11 active agent is not well absorbed, the continuous release of active agent in  
12 the stomach over a prolonged time period will dispense active agent over that  
13 same period of time to the small intestine where it can be absorbed.

14         The physiological behavior of the stomach is usually determined by  
15 whether it contains food or is empty. Food is mixed and partially digested in  
16 the distal stomach (antrum). As the stomach undergoes contractions,  
17 partially digested material is discharged into the small intestine and non-  
18 digested material is retropelled into the main part of the stomach for further  
19 digestion. In the fed state, non-digested material is not generally able to  
20 leave the stomach. At the end of a digestive period, the stomach enters the  
21 fasting stage and begins a cycle called the interdigestive myoelectric motor  
22 cycle or IMMC.

23         The IMMC can be considered to be divided into four phases: (1) phase  
24 1 is an approximately one hour period with no contractions; (2) phase 2 is  
25 about a forty minute period of intermittent potentials and contractions that  
26 increase in intensity over time; (3) phase 3 is a relatively short period,  
27 generally between about five to fifteen minutes, of intense contractions  
28 (commonly called the "housekeeper wave") that completely empties the  
29 stomach; and (4) phase 4 is a short transitory period between the intense  
30 activity of phase 3 and the quiescence of phase 1. The different phases  
31 move distally from the stomach to the terminal ileum over an approximately

1 two hour period as the cycle is repeated. Since the cycle is interrupted by the  
2 receipt of food by the stomach, it is possible to delay the emptying phase,  
3 phase 3, by maintaining a fed state. However, it is not practical to regularly  
4 maintain the fed state over a long period of time. Consequently, a need  
5 exists for a delivery device that can remain in the stomach for a significant  
6 period, whether in the fed or fasted state, and deliver active agent to the  
7 stomach over a prolonged period of time.

8 A variety of studies have been conducted in dog and in man to  
9 determine sizes of objects that would be retained in the stomach during the  
10 fed stage and also in the fasting stage when IMMC is present. Khosla and  
11 Davis, International Journal of Pharmaceutics, Vol. 62 (1990), pages R9-R11  
12 have reported that a particle size less than 2 mm generally results in emptying  
13 from the stomach of the dog. Non-disintegrating tablets having sizes of 7, 11  
14 and 13 mm in diameter were emptied from the human stomach, but the larger  
15 sized tablets tended to remain in the stomach longer than the small sized  
16 tablets. Tablets larger than 11 mm tended to be emptied only during the  
17 IMMC. Davis et al., Pharmaceutical Research, Vol. 8, No. 10 (1991) has  
18 described retention of radio-telemetry capsules having a size of 25 x 8 mm in  
19 the stomach of human subjects past phase 3 of the IMMC. Timmermans et  
20 al., Journal of Pharmaceutical Sciences, Vol. 82, No. 8 (1993) has reported  
21 the mean resting pyloric diameter in humans as  $12.8 \pm 7.0$  mm. Accordingly,  
22 it is important that gastric retentive delivery vehicles are adapted to  
23 disintegrate, dissolve or erode to sizes that permit eventual elimination of the  
24 vehicle without causing gastric obstruction.

25 Various attempts to provide active agent delivery devices that remain  
26 in the stomach for extended periods or time have been described previously.  
27 For example, U.S. Patent No. 4,851,232 describes a hydrogel reservoir  
28 containing tiny pills having a active agent core surrounded by a wall  
29 controlling delivery of active agent to the stomach. The hydrogel swells in the  
30 stomach to facilitate retention of the active agent reservoir in the stomach  
31 over time.

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100

5  
6  
7  
8  
9  
10  
11  
12

13  
14  
15  
16  
17  
18  
19

[illegible]

	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

[illegible]

- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29

17  
18  
19  
20  
21  
22  
23  
24

25  
26  
27  
28  
29

30  
3

1 at a rate that is governed by the fluid induced relaxation of a polymeric agent  
2 contained within the dispenser. The cylindrical dispenser includes an  
3 impermeable container that has within it a reservoir and a passageway from  
4 the reservoir to the exterior of the container. The reservoir contains a  
5 polymer and a beneficial agent. The polymer imbibes fluid from the  
6 environment and thereby undergoes relaxation, releasing the beneficial agent  
7 from the device. The amount of agent released is dependent on the rate of  
8 relaxation of the polymer over time.

9 Coated dosage forms have also been suggested for delivery of a  
10 controlled amount of a beneficial agent over a prolonged period of time. U.S.  
11 Patent No. 5,256,440 describes a process for producing a film coated dosage  
12 form. A continuous groove is inscribed in a dosage form core. A latex film is  
13 coated onto the core, the groove defining a fixed zone and a detachable zone  
14 for the film. The detachable portion of the latex film detaches when it is  
15 exposed to the environment of use, thereby exposing a discrete portion of the  
16 dosage form core surface. The remainder of the film remains attached to the  
17 dosage form core. The exposed portion of the dosage form surface erodes  
18 and releases active agent to the environment of use.

19 Coated tablets for constant and prolonged active agent release are  
20 described by Conte et al in J. Controlled Release, Vol. 26, (1993) pages 39-  
21 47. These GEOMATRIX™ Systems are swellable matrices that are coated or  
22 tableted with polymeric barrier layers. Release performances of the systems  
23 are modulated as a result of the reduction of the releasing surface exposed to  
24 the dissolution medium by the polymeric barrier layer coatings. As the extent  
25 of coating of the system's surface is increased, the release kinetics of the  
26 system shift toward constant release. These systems are further described in  
27 U.S. Patent No. 4,839,177 to Colombo et al.

28 U.S. Patent No. 5,780,057 describes a ~~one or two~~ <sup>two or three</sup> layered tablet where  
29 at least one of the layers swells by contact with biological fluids to promote  
30 retention of the tablet in the stomach where the active ingredient may be  
31 slowly released. The description indicates that at least one of the layers acts

1 as a barrier for a predetermined period of time to the active agent that is  
2 contained one of the other layers.

3 U.S. Patent No. 5,534,263, which is incorporated herein by reference,  
4 describes a dosage form useful for the prolonged delivery of an active agent  
5 formulation in the form of a matrix having two or more insoluble bands on the  
6 surface of the matrix. The exposed surfaces of the matrix erode in a manner  
7 that creates additional surface areas to provide for prolonged release of an  
8 active agent formulation with determined release profiles. That patent is not  
9 concerned with dosage forms that are retained in the stomach for a prolonged  
10 period of time.

11 Additional oral, controlled-release dosage forms include elementary  
12 osmotic pumps, such as those described in U.S. Patent No. 3,845,770, mini-  
13 osmotic pumps such as those described in U.S. Patents Nos. 3,995,631,  
14 4,034,756 and 4,111,202, and multi-chamber osmotic systems referred to as  
15 push-pull, push-melt and push-stick osmotic pumps, such as those described  
16 in U.S. Patents Nos. 4,320,759, 4,327,725, 4,449,983, 4,765, 989, 4,892,778,  
17 4,940,465, 4,915,949 and 5,126,142, all of which are incorporated herein by  
18 reference.

19 Administration of acyclovir by sipped solution over a four-hour period  
20 has been described in Br. J. clin. Pharmac., 21, 459-462 (1986) to achieve an  
21 increased contact time with the human stomach and the gastrointestinal tract.  
22 The total amount of acyclovir absorbed was increased over that observed  
23 with administration of acyclovir tablets. However, continuous oral  
24 administration requiring the interaction of the patient is not what would  
25 generally be considered suitable therapy. The influence of food on gastric  
26 retention time and the absorption of acyclovir has been reported in  
27 International Journal of Pharmaceutics, Vol. 38 (1987), pages 221-225. As  
28 reported there, compared to a lighter meal, the heavier meal slowed the rate  
29 of gastric emptying, prolonged small intestinal transit time and decreased  
30 absorption of the active agent.

ARC 2885 R1

## SUMMARY OF THE INVENTION

As can be observed in the above-referenced patents and publications, devices have been described that provide for prolonged delivery of an active agent and retention in the gastric environment. However, there remains a continuing need for improved systems for delivering an active agent to the gastric environment over a prolonged period of time and in a reliable, controllable and reproducible manner.

In one aspect, the invention comprises an active agent dosage form adapted for gastric retention comprising (a) a first layer comprising a swellable, water-soluble polymer, (b) a second layer comprising a therapeutically-effective amount of an active agent, the second layer being laminated with the first layer at a common surface, and (c) at least one band of insoluble material circumscribing and binding together the first layer and the second layer, the first layer being adapted to swell in the stomach to facilitate retention of the dosage form in the stomach over a prolonged period of time. Preferably, the release of the active agent from the second layer is independent of the composition of the first layer and occurs over a prolonged period of time. Examples of water soluble polymers include polyethylene oxide, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, sodium carboxy methylcellulose, calcium carboxymethyl cellulose, methyl cellulose, polyacrylic acid, maltodextrin, pre-gelatinized starch, guar gum, sodium alginate, or polyvinyl alcohol, and most preferably high molecular weight polyethylene oxide, e.g., Polyox® brand of polyethylene oxide (Union Carbide Corporation, Danbury, Connecticut). The first layer preferably swells more rapidly and to a greater extent than does the second layer. The first layer may be gel-like and exhibit a slippery external surface.

In another aspect, the first or second layers of the above-described dosage form comprises a hydroattractant selected from low-substituted hydroxypropyl cellulose, microcrystalline cellulose, cross-linked sodium or calcium carboxymethyl cellulose, cellulose fiber, cross-linked polyvinyl pyrrolidone, cross-linked polyacrylic acid, cross-linked Amberlite resin,

1 alginates, colloidal magnesium-aluminum silicate, corn starch granules, rice  
2 starch granules, potato starch granules, pregelatinized starch, sodium starch  
3 glycolates, guar gum, soybean fiber, psyllium husk fiber, rice husk fiber,  
4 wheat fiber, alginic acid derivatives such as sodium alginate and alginic acid,  
5 silicates such as bentonite, colloidal magnesium and aluminum silicate  
6 (Veegum), gelatin, cross-linked gelatin, sodium carboxymethyl starch, sugars  
7 and sodium chloride.

8 In another aspect, the invention comprises the dosage form as  
9 described above wherein the weight percent of the water soluble polymer in  
10 the first layer is about 5 to 100 weight percent and weight percent of the  
11 hydroattractant in the first layer is about 0 to 60 weight percent, and the  
12 weight percent of the water soluble polymer in the second layer is about 5 to  
13 95 weight percent and the weight percent of the hydroattractant is about 5 to  
14 70 weight percent. The dosage form of the invention releases the active  
15 agent over a prolonged period time of at least about 3 hours, more often  
16 between 8 to 12 hours.

17 In still another aspect, the second layer may be formed of a plurality of  
18 sublayers, each containing differing amounts of active agent or different  
19 active agent or each being of different thickness to provide active agent  
20 release profiles that vary with time.

21 In a further aspect, the invention comprises a method of treating a  
22 subject in need thereof with an active agent that comprises administering to  
23 the subject a multilayered dosage form adapted to be retained in the stomach  
24 over a prolonged period of time, the dosage form comprising a first layer  
25 adapted to swell in the stomach of the subject and retain the dosage form in  
26 the stomach for a prolonged period of time, and a second layer adapted to  
27 deliver to the subject an active agent at a variable rate of delivery. The  
28 second layer may be comprised of multiple laminates, each having a different  
29 active agent concentration per unit volume and/or different thickness. The  
30 method may comprise administering one or more dosage forms to the subject  
31 in the fed state at the start of each dosing period, such as within one hour of

the subject consuming food.

DESCRIPTION OF THE DRAWINGS

The figures are not drawn to scale, but are set forth to illustrate various embodiments of the invention. Like numbers refer to like structures.

FIG. 1 is a schematic illustrating a dosage form of the present invention;

FIG. 2 is a schematic of bilayer core of the dosage form prior to completion of fabrication of the dosage form;

FIG. 3 is a completed dosage form of the invention;

FIG. 4 illustrates the dosage form of the invention soon after administration where the retention layer of the dosage form and the drug layer have swelled to substantially maximum dimensions;

FIG. 5 illustrates the dosage form of the invention at an intermediate time after administration where the retention layer and the drug layer have eroded or dissolved in the stomach environment, but at a stage where the retention layer is still large enough to effectively maintain the dosage form in the stomach;

FIG. 6 illustrates the dosage form at a later time than illustrated in Figure 5, when the retention layer has eroded or dissolved to an extent that the dosage form may be expelled from the stomach through the pylorus;

FIG. 7 illustrates a representative profiles of the concentration of minocycline in the plasma of dogs from the bilayer dosage form of the invention described in Example 8 and a mono-system, also described in Example 8, in which the drug is incorporated into the expandable layer to form a mono-system;

FIGs. 8A and 8B illustrate a representative *in vitro* release rate profile and the corresponding cumulative release, respectively, for the drug fexofenadine hydrochloride from a form of the invention illustrated in Figs. 1 in which the retention layer is prepared from Polyox 303 and the drug layer is prepared from Polyox WSR N-60K and low substituted

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100

2  
3  
4  
5  
6  
7

8  
9  
10

11  
12

13  
1  
1  
1  
1  
1  
1  
2  
2  
2

**2**

[illegible]

1 agent from the dosage form without compromising the rate at which the  
2 swollen polymer matrix is eroded or dissolved in the stomach and  
3 consequently reduce the retention time below acceptable levels.

4 Accordingly, it has been surprisingly discovered that the dosage form  
5 of this invention may be fabricated with an individual portion that does not  
6 contain active agent and an individual portion that does contain active agent,  
7 those two portions being laminated together and further joined by an insoluble  
8 band that maintains the separate portions together during the prolonged  
9 period in which the dosage form is retained in the stomach; that the dosage  
10 form may be loaded with large amounts of active agent when the clinical  
11 application requires; that the dosage form will be retained in the stomach over  
12 a prolonged period; and that the dosage form will be effective with separate  
13 portions having different swelling, erosion and dissolution characteristics.  
14 The particular improvements and characteristics comprising the invention are  
15 described below.

#### 16 Definitions

17  
18 The phrase "prolonged period" or "prolonged period of time" intends a  
19 time period that lasts for several hours to about 24 hours, usually up to about  
20 12 hours, and often between about 3 and 14 hours, and most often at least 6  
21 hours.

22 The phrase "prolonged delivery" intends a duration of delivery  
23 extending over a time period that lasts for several hours to about 24 hours,  
24 usually up to about 12 hours, and often between about 3 and 14 hours, and  
25 most often at least 6 hours.

26 By "insoluble" is intended a material that will not substantially dissolve  
27 in the environment of use during the delivery period.

28 The term "active agent" refers to an agent, drug, compound or other  
29 substance, or compositions and mixtures thereof, that provide some  
30 pharmacologic, often beneficial, effect. Reference to a specific active agent  
31 shall include where appropriate the active agent and its pharmaceutically

1 acceptable salts.

2 The term "polymer matrix" as used herein means a water soluble, high  
3 molecular weight polymer and, optionally, a hydroattractant in admixture  
4 therewith.

5 The term "active agent formulation" intends the active agent or the  
6 active agent optionally in combination with pharmaceutically acceptable  
7 carriers and additional inert ingredients.

8 The terms "adapted for gastric retention" or "gastric retentive" mean,  
9 with respect to the dosage form of this invention, that the dosage form will  
10 remain in the stomach of a subject for a prolonged period of time.

11 The terms "rigid" and "semi-rigid" mean, with respect to a portion of the  
12 polymer matrix as defined above, that such portion will not swell and form a  
13 gel when initially contacted with gastric fluid.

14 The term "bioerodible" intends a material that will, at least in part,  
15 dissolve, degrade or erode in the fluid environment of use.

16 The term "bioequivalent" intends, with respect to an active agent  
17 dosage form of this invention, that there is greater than a 90% probability that  
18 the bioavailability of the active agent as determined by standard methods is  
19 80-125% of the defined dosage form and that there is greater than a 90%  
20 probability that the maximum blood plasma concentration and the minimum  
21 blood plasma concentration of the active agent as measured by standard  
22 methods is 80-125% of the defined dosage form.

23 The term "polymer" means a material formed from a single polymer or  
24 a mixture of polymers.

25 The term "swellable" means, with respect to a polymer or a polymer  
26 matrix, that the polymer or polymer matrix is capable of imbibing fluid and  
27 expanding when in contact with fluid present in the environment of use.

28 The terms "therapeutically effective" amount or rate refer to the amount  
29 or rate of the active agent needed to effect the desired pharmacologic, often  
30 beneficial, result.

31 The invention will be better understood with reference to the drawings

1 and the description herein.

2 FIG. 1 depicts one embodiment of the delivery device 10 according to  
3 the present invention. The delivery device or active agent dosage form 10  
4 comprises a first layer 12 of material that swells upon imbibing fluid and a  
5 second layer 14, laminated at a common surface 15. The first layer 12  
6 conveniently is formed of a highly swellable polymer which will initially swell  
7 upon imbibing fluid and subsequently dissolve or erode after administration in  
8 the stomach of a subject over a prolonged period of time. Second layer 14  
9 comprises a therapeutic agent, most often dispersed or dissolved in a carrier.  
10 Second layer 14 may be formed of material that swells to some extent in the  
11 stomach and which also will dissolve or erode in the environment of use, i.e.,  
12 primarily in the stomach of the subject to whom the dosage form has been  
13 administered. In most instances, the material forming first layer 12 will swell  
14 to a greater extent than that the material forming second layer 14. A band 18  
15 circumscribes the two layers 12 and 14 and maintains the two layers together  
16 during operation. This is particularly important since the different swelling  
17 characteristics of layers 12 and 14 may create a tendency toward  
18 delamination and separation at the common surface 15. Band 18 typically is  
19 insoluble and provides a certain degree of rigidity near the central portion of  
20 the dosage form because of the inability of the first and second layers to swell  
21 to any appreciable extent in the area under the band. Optionally, a soluble  
22 coating 16 may be applied to the two layers prior to the banding process to  
23 provide a smooth surface that facilitates swallowing of the dosage form. Also,  
24 an optional second, soluble coating (not shown) may be applied over the  
25 completed dosage form to provide a continuously smooth external surface.

26 Representative examples of the swellable polymer comprising high  
27 molecular weight, water-soluble polymers useful for the fabrication of first  
28 layer 12 are polyethylene oxide and cellulosic polymer derivatives including  
29 hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl  
30 cellulose, sodium carboxy methylcellulose, calcium carboxymethyl cellulose,  
31 methyl cellulose, as well as noncellulosics such as maltodextrin, polyvinyls,

1 polyvinyl alcohol, polyacrylic acids, alginates, gelatin, natural gums, including  
2 guar, lightly crosslinked versions of these polymers, starches, starch graft  
3 copolymers and the like. The polymers generally have number average  
4 molecular weights over 50,000 grams per mole, such as between 50,000 and  
5 10,000,000 grams per mole and representative viscosities, e.g. for  
6 polyethylene oxide in the range of 12-20,000 cps (5% aq, 25°C, MW 100,000-  
7 900,000), 400-4000 cps (2% aq, 25°C, MW 1,000,000 - 2,000,000) and 1500-  
8 15,000 cps (1% aq, 25°C, MW 4,000,000 - 8,000,000) [Brookfield viscometer,  
9 rotational spindle]; for methylcellulose in the range of 1,500-18,000 cps (2%  
10 aq, 20°C, MW 62,000-134,000) [Ubbelohde tube viscometer]; for  
11 hydroxypropyl methylcellulose in the range of 4,000-100,000 cps (2% aq,  
12 20°C, MW 88,000-242,000) [Ubbelohde tube viscometer]; for hydroxyethyl  
13 cellulose in the range of 75-400 cps (5% aq, 25°C, MW 90,000-200,000),  
14 400-6500 cps (2% aq, 25°C, MW 300,000 - 720,000) and 1500-5,000 cps  
15 (1% aq, 25°C, MW 1,000,000 - 1,300,000) [Brookfield viscometer, rotational  
16 spindle]; for guar about 5100 cps (1%) [Brookfield viscometer, rotational  
17 spindle]; for poly(methyl vinyl ether/maleic anhydride) in the range of 15 to  
18 greater than 200 cps (5% aq., MW 20,000-80,000) [Brookfield viscometer,  
19 rotational spindle]; for polyvinyl alcohol in the range 27-65 cps (4%aq, 20°C  
20 [Hoeppler falling ball method and 1100-1500 cps (10%aq, 25°C) [Brookfield  
21 viscometer, rotational spindle]; for sodium carboxymethyl cellulose in the  
22 range of 25-50 cps (2% aq, 25°C) (MW 90,000) to about 2,500-6,000 cps (1%  
23 aq, 25°C) (MW 700,000) [Brookfield viscometer, rotational spindle]; and for  
24 sodium polyacrylic acid 5000-80,000 (0.5% aq) ( MW 750,000 -  
25 4,000,000,000) [Brookfield viscometer, rotational spindle]. Polymers having  
26 molecular weights between 300,000 and 8,000 000 grams per mole are  
27 preferred, and those having molecular weights between about 2,000,000 to  
28 8,000,000 grams per mole are especially preferred. Polyethylene oxide  
29 having a number average molecular weight between about 5,000,000 to  
30 8,000,000 grams per mole is most especially preferred, e.g. Polyox 303 and

1 Polyox 308. Also, especially preferred are methylcellulose type/grade A15C,  
2 A4M, A18M and hydroxypropyl methylcellulose type/grade K4M, K15M,  
3 K100M, E4M and F4M (Dow Chemical Company); hydroxyethyl cellulose  
4 such as Natrosol® HEC; hydroxypropyl cellulose such as Klucel (Grades H,  
5 M, G, J, L, E - Aqualon Company); guar such as Supercol® Guar U (Aqualon  
6 Company); pectin such as GENU Pectin (Aqualon Company); carrageenan  
7 such as GENU Carrageenan (Aqualon Company); poly(methyl vinyl  
8 ether/maleic anhydride) such as Gantrez® AN Copolymer (AN-119, -139, -  
9 149, -169, -179, GAF Corporation); polyvinyl alcohol such as Elvanol® 71-30,  
10 Elvanol® 85-80, Elvanol® 55-65, Elvanol® 50-42 and Elvanol® HV (DuPont);  
11 sodium carboxymethyl cellulose such as Aqualon cellulose gum grade 7H4;  
12 polyacrylic acids such as Carpobol® resin grades 934P, 940, 941, 971P,  
13 974P, 980, 981, 1382, 2984, 5984, ETD 2001, ETD 2050, calcium polyacrylic  
14 acids such as Noveon® resin grades AA-1, CA-1 and CA-2, and sodium  
15 polyacrylic acid (BF Goodrich, Cleveland, Ohio).

16         Polymers that impart a surface lubricity to first layer 12 are especially  
17 preferred, and may be exemplified by polyethylene oxides sold under the  
18 trademark Polyox, e.g. Polyox 303 and Polyox 308. The combination of  
19 surface lubricity, the gel-like nature of the swollen polymer, the rigid section of  
20 the dosage form provided by band 18 and the resulting non-swollen section of  
21 the dosage form, and the particular size parameters of the swollen dosage  
22 form all appear to contribute to the characteristic of the dosage form to be  
23 retained in the stomach for a prolonged period of time.

24         First layer 12 may be formed with a hydroattractant mixed with the  
25 water soluble polymer. Representative hydroattractants, that may be used  
26 are described below with regard to the second layer 14. The use of a  
27 hydroattractant generally facilitates rapid swelling of first layer 12 in the  
28 stomach and generally provides a greater assurance that the dosage form will  
29 attain a swollen size after administration that resists expulsion through the  
30 pylorus. Fiberlike hydroattractants additionally serve to impart a fiber  
31 reinforced gel structure.

60227-602960

1           Second layer 14 may also conveniently be formed of a polymer base  
2 that swells to some extent to allow for erosion and dissolution in the  
3 environment of use to facilitate release of the active agent in a controlled  
4 fashion. Polymers of the classes described for first layer 12 may be utilized.  
5 However, generally polymer materials that do not swell to the same extent as  
6 those employed in first layer 12 will be utilized. More limited swelling allows  
7 for increased quantities of active agent to be loaded into the second layer 14  
8 than would otherwise be possible. Preferred materials include the water  
9 soluble polymers such as described above, particularly the polyethylene  
10 oxides having molecular weights of between about 100,000 to 900,000 are  
11 preferred.

12           The second layer 14 may also preferentially include a hydroattractant  
13 to draw in water from the environment of use to facilitate release of active  
14 agent when the active agent is present initially in a dry state. When active  
15 agent is provided in a liquid, active agent formulation, as will be described  
16 later, the use of a hydroattractant may be optional, since the carrier in which  
17 the particles containing the liquid, active agent formulation typically will  
18 dissolve or erode to allow the particles to be released to the environment of  
19 use, and subsequently release active agent at the absorption site.

20           Representative examples of hydroattractants are water-insoluble  
21 polymers such as low substituted hydroxypropyl cellulose, microcrystalline  
22 cellulose (Avicel), cross-linked sodium or calcium carboxymethyl cellulose,  
23 cellulose fiber (Solka-Floc, Arbocel or Elcema), cross-linked polyvinyl  
24 pyrrolidone (Polyplasdone XL), cross-linked Amberlite resin, alginates  
25 (Satialgine), colloidal magnesium-aluminum silicate (Veegum), corn starch  
26 granules, rice starch granules, potato starch granules, wheat starch granules,  
27 sodium carboxymethyl starch (Expotab, Primojel), corn  
28 starch/acrylamide/sodium acrylate copolymer, acrylamide/sodium acrylate  
29 copolymer and the like. A particularly suitable hydroattractant is  
30 hydroxypropyl cellulose having a hydroxypropyl content of between about 8-  
31 15 weight percent, and preferably about 10-13 weight percent, such as that

1 supplied as Low Substituted Hydroxypropyl Cellulose grade 11 as  
2 manufactured by Shin-Etsu Chemical Company, Ltd., Tokyo, Japan.  
3 Optionally, non-polymeric water-soluble hydroattractants can be incorporated  
4 into layer 12. These include sodium chloride, sugars such as sorbitol,  
5 mannitol, glucose, maltose, sucrose, lactose, acids such as citric acid, tartaric  
6 acid, succinic acid, gas-generating agents such as sodium or potassium  
7 bicarbonate which react with gastric fluids to produce carbon dioxide gas, and  
8 the like.

9 As noted earlier, optionally, hydroattractants, such as those described  
10 above, may be included in the first layer 12 as well. Hydroxypropyl cellulose  
11 having a hydroxypropyl content of between 8-15 weight percent is preferred,  
12 and most preferred are those having a hydroxypropyl content of about 10-13  
13 weight percent, such as Low Substituted Hydroxypropyl Cellulose grade 11  
14 exemplified above.

15 Typically, the water soluble, high molecular weight polymer in the  
16 polymer matrix of the first layer 12 is present in from about 5% to about 100%  
17 by weight based on the total weight of layer 12. Typically, the water soluble  
18 polymer forming layer 14 is present in from about 5% to about 90% of the  
19 active agent formulation layer 14, and the hydroattractant is present in from  
20 about 5% to about 70% by weight based on the total weight of the active  
21 agent formulation layer 14. The particular percentages will be chosen to  
22 provide the desired retention time in the stomach and the desired release  
23 profile of active agent. However, it is presently preferred to have the polymer  
24 matrix forming layer 12 contain about 50% of a highly swellable, water soluble  
25 polymer, 25% of cellulose fiber and 25% sodium chloride, and the polymer  
26 matrix forming second layer 14 contain from about 10 weight percent to about  
27 50 weight percent of the water soluble, high molecular weight polymer and  
28 from about 10 weight percent to about 60 weight percent of the  
29 hydroattractant. Weight percentages of water soluble, high molecular weight  
30 polymer in the range of 10 to 40 weight percent and hydroattractant in the  
31 range of 25 to 35 in second layer 14 are especially preferred, the remaining

1 percentage being active agent or an active agent composition.

2 Dosage form 10 is conveniently cylindrically shaped with rounded ends  
3 that facilitate administration of the dosage form in its non-swollen state. In  
4 FIG. 2, the device 10 is shown in preparation, without the addition of an  
5 overcoat, prior to application of the insoluble material or band 18 shown in  
6 FIG. 3. The insoluble material exemplified as band 18, circumscribes a  
7 portion of the outer surface of the dosage form 10, including both layer 12  
8 and layer 14. While a single band is illustrated in FIG. 3, additional bands can  
9 be utilized depending on the particular application for which the device is  
10 being used. For ease of illustration, optional coating 16 and any optional  
11 overcoat have been omitted in FIGs. 2-6.

12 The band of insoluble material 18 is applied to the outer surface of the  
13 layers 12 and 14. The insoluble material imparts rigidity particularly to the  
14 gel-forming polymer matrix forming layer 12 to manage gastric retention time  
15 and further control the delivery profile of the active agent of interest from layer  
16 14. Band 18 typically exhibits low water permeability and will prevent that  
17 portion of the polymer matrices which it surrounds from imbibing fluid, thus  
18 substantially limiting any swelling of the polymer matrix of layers 12 and 14 at  
19 that location. In addition, given that the layers 12 and 14 often may be  
20 formed of different materials having rates of swelling that tend to delaminate  
21 the dosage form at the common surface 15, band 18 also serves to retain the  
22 two layers together and maintain the integrity of the dosage form 10 during  
23 most of its lifetime. The number, size, and placement of the insoluble bands  
24 that are applied may be varied to adjust the active agent delivery profile and  
25 the retention time in the stomach. For example, bands 0.1 mm to about 12  
26 mm in width, preferably between about 0.5 and 8 mm, may be applied onto  
27 the active agent formulation matrix surface. Further, between about 1 and 10  
28 bands may be used, but generally between about 1 and 3 are affixed to the  
29 bilayer core. The bands may be placed close together (i.e., within about 0.5  
30 mm of each other) or may be placed about 8 to 12 mm apart.

31 FIG. 4 illustrates dosage form 10 in its initial configuration after it has

1 imbibed fluid and swelled in those areas not surrounded by band 18. Because  
2 of the low fluid impermeability of band 18, the portion of dosage form 10  
3 surrounded by band 18 does not appreciably imbibe fluid and the polymer in  
4 such portion of the dosage form does not swell to any significant extent.  
5 FIG. 5 illustrates a sequential state of dosage form 10 after it has begun to be  
6 eroded by or dissolve in the gastric fluid. FIG. 6 illustrates the dosage form  
7 after it has been substantially eroded by gastric fluid and contractions of the  
8 stomach. Eventually, dosage form 10 will be reduced to such a size as to  
9 enable it to be expelled from the stomach.

10 The insoluble material comprising band(s) 18 may be any material that  
11 is nontoxic, biologically inert, nonallergenic and nonirritating to body tissue,  
12 that exhibits little impermeability to liquids, and that maintains its physical and  
13 chemical integrity in the environment of use for at least a portion of the  
14 dispensing period. The bands may be formulated with neutral charge  
15 polymers which are insoluble in gastric fluid or may be formulated with  
16 anionic polymers which are insoluble in gastric fluid and dissolve in intestinal  
17 fluid. The low liquid permeability of the insoluble material serves to limit  
18 swelling of the polymer matrix in that section of the polymer matrix that is  
19 surrounded by the band.

20 Insoluble materials from which the bands may be prepared include, for  
21 example, polyethylene, polystyrene, ethylene-vinyl acetate copolymers,  
22 polycaprolactone and Hytrel® polyester elastomers (Du Pont). Additional  
23 banding materials include but are not limited to polysaccharides, cellulose,  
24 cellulose acetate, cellulose acetate propionate, cellulose acetate phthalate,  
25 cellulose acetate butyrate, cellulose acetate pseudolatex (such as described  
26 in U.S. Patents 4,931,285 and 5,024,842), ethyl cellulose, ethyl cellulose  
27 pseudolatex (such as Surelease® as supplied by Colorcon, West Point, PA or  
28 Aquacoat™ as supplied by FMC Corporation, Philadelphia, PA),  
29 nitrocellulose, polylactic acid, poly- glycolic acid, polylactide glycolide  
30 copolymers, polycaprolactone, polyvinyl alcohol, polyvinyl acetate,  
31 polyethylene vinylacetate, polyethylene terephthalate, polybutadiene styrene,

1 polyisobutylene, polyisobutylene isoprene copolymer, polyvinyl chloride,  
2 polyvinylidene chloride-vinyl chloride copolymer, copolymers of acrylic acid  
3 and methacrylic acid esters, methacrylic acid copolymers, copolymers of  
4 methylmethacrylate and ethylacrylate, ammoniomethacrylate copolymer, latex  
5 of acrylate esters (such as Eudragit® supplied by RöhmPharma, Weiterstadt,  
6 Germany), polypropylene, copolymers of propylene oxide and ethylene oxide,  
7 propylene oxide ethylene oxide block copolymers, ethylenevinyl alcohol  
8 copolymer, poly sulfone, ethylene vinylalcohol copolymer, polyxylylenes,  
9 polyamides, rubbers, such as styrenebutadiene, polyisobutylene and the like,  
10 natural and synthetic waxes, paraffin, carnauba wax, petroleum wax, white or  
11 yellow bees wax, castor wax, candelilla wax, rice bran wax, microcrystalline  
12 wax, stearyl alcohol, cetyl alcohol, bleached shellac, esterified shellac, chitin,  
13 chitosan, silicas, polyalkoxysilanes, polydimethyl siloxane, polyethylene  
14 glycol-silicone elastomers, crosslinked gelatin, zein, electromagnetic  
15 irradiation crosslinked acrylics, silicones, or polyesters, thermally crosslinked  
16 acrylics, silicones, or polyesters, butadiene-styrene rubber, glycerol ester of  
17 partially dimerized rosin, glycerol ester of partially hydrogenated wood rosin,  
18 glycerol ester of tall oil rosin, glycerol ester of wood rosin, pentaerythritol ester  
19 of partially hydrogenated wood rosin, pentaerythritol ester of wood rosin,  
20 natural or synthetic terpene resin and blends of the above.

21 The banding materials often are also formulated with plasticizers, and  
22 optionally with wetting agents, surfactants, opacifiers, colorants, flavorants,  
23 taste-masking agents, and the like. Examples of typical plasticizers are as  
24 follows: polyhydric alcohols, polyethylene glycol, glycerol, propylene glycol,  
25 acetate esters, glycerol triacetate, triethyl citrate, acetyl triethyl citrate, tributyl  
26 citrate, acetyl tributyl citrate, triacetin, glycerides, acetylated monoglycerides,  
27 oils, mineral oil, castor oil, PEG castor oil, and the like.

28 Referring again to the embodiment of the invention depicted in FIG. 3,  
29 dosage form 10 in its non-swollen state has a length L1 and a maximum  
30 diameter D1. FIG. 4 shows dispensing device 10 after having been placed in  
31 the stomach.

1 After swelling, the dosage form 10 has a length L2 and a maximum  
2 diameter D2 measured at the widest part of the swollen polymer matrices, as  
3 illustrated in FIG. 4. Generally, for human applications the largest dimension  
4 of the device in the swollen state equivalent to the diameter D2 should be  
5 greater than 7 mm, preferably 10 mm or greater, and most preferably 13 mm  
6 or greater during the period of residence in the stomach when active agent is  
7 being dispensed. Since the active agent formulation is intended to remain in  
8 the stomach for a prolonged period, the effective diameter of the active agent  
9 dosage form when in its swollen state in the stomach may have to be  
10 significantly larger than 13 mm, and may extend to more than 50 mm or  
11 greater. Larger dosage forms may be appropriate particularly when the  
12 polymer matrix is designed to erode relatively rapidly over time in order to  
13 provide the required delivery of active agent for therapeutic effect.

14 In contrast to the exposed segments of the swollen polymer matrices,  
15 band 18 and the portion of the polymer matrices beneath it do not swell  
16 significantly. Accordingly, that segment of the dosage form surrounded by  
17 band 18 is maintained in a constrained and more compressed, non-swollen  
18 state than the unbanded portion of the matrices. Since band 18 does not  
19 take up an appreciable amount of fluid from the stomach and swell, band 18  
20 retains its substantially rigid or semi-rigid form, and provides an element of  
21 rigidity to the dosage form as a whole. While it is not entirely clear how band  
22 18 and the constrained segment of the polymer matrices of layers 12 and 14  
23 facilitate retention of the dosage form in the stomach through housekeeping  
24 waves, it is thought that the band reduces the rate of erosion of the polymer  
25 matrices, thus maintaining a larger effective size of the dosage form and  
26 reducing the chance for its expulsion from the stomach, for a longer period of  
27 time than would otherwise occur if the band was not present. Additionally, the  
28 presence of the band on the polymer matrices provides a semi-rigid segment  
29 of the dosage form that appears to permit the dosage form to be retropelled  
30 into the main area of the stomach as a reaction to the stomach contractions  
31 rather than being expelled by the housekeeping wave, as a less rigid gel

1 would be inclined to be.

2 For applications in animals other than humans, for example in dogs,  
3 the maximum diameter should be greater than about 2 mm. The maximum  
4 dimension for any particular dosage form will depend on the particular  
5 application and animal in which the device is being used. Such dimensions  
6 can be determined by those skilled in the art in accordance with the teaching  
7 herein and the various patents and publications noted herein and existing in  
8 the related art.

9 A practical consideration, particularly for oral administration to humans,  
10 is that the initial size of the device be such that it can be reasonably,  
11 comfortably swallowed. For human oral applications, a preferred size of the  
12 device in its form prior to administration to the stomach would be on the order  
13 of a size 000 capsule to a size 5 capsule. However, it is understood that  
14 smaller or larger sizes could be used for particular applications where  
15 necessary. Since the dosage forms of the invention may be gel-forming, it  
16 may be desirable to wet the outer surface of the dosage form immediately  
17 prior to the subject swallowing the dosage form in order to provide a more  
18 slippery outer surface and promote ease of swallowing. Alternatively, the  
19 bilayer core can be inserted into a hard gelatin capsule prior to application of  
20 the band in order to facilitate swallowing and also promote ease of  
21 manufacture in applying and forming the bands. Upon entering the stomach,  
22 that portion of the hard gelatin capsule that is not covered by the band will  
23 dissolve, exposing the polymer matrices to fluid in the stomach. As the  
24 polymers imbibe fluid, the dosage form will swell in the exposed segments as  
25 previously described. The dosage form typically is prepared to allow for  
26 swelling at a controlled rate, particularly at a limited initial rate, so that the  
27 dosage form does not swell inordinately during the swallowing process and  
28 result in obstruction of the esophagus.

29 The configuration of the multilayer dosage form is selected to achieve  
30 the delivery duration and gastric retention period targeted for a particular  
31 drug. Generally, the bilayer compressed tablet is fabricated such that the

606227 000000

1 dimensions and proportions of the tablet resemble those of a hard gelatin  
2 capsule. For example, where the dosage form is fabricated to dimensions  
3 comparable to a size 0 capsule, dimension D1 illustrated in FIG. 3 represents  
4 a value of approximately 8 mm. The thickness of the drug layer can be  
5 selected such that it represents a range of  $0.05D1$  to  $0.95D1$ . The drug layer  
6 most commonly represents a thickness in the range of  $0.2D1$  to  $0.8D1$ , with a  
7 thickness of  $0.5D1$  to  $0.7D1$  being especially preferred. The drug layer may  
8 itself be divided into a number of layers (for example, two to four sublayers)  
9 and fabricated using conventional multilayer tableting presses. The individual  
10 sublayers may be varied in number and thickness, generally within the overall  
11 dimensional ranges set forth above, and each sublayer may have varying  
12 drug concentrations of the same or different drugs to alter the delivery  
13 profile(s) of the drug(s). One or more of the sublayers may be inert if a  
14 pulsed delivery of drug is desirable; or, the first, outer sublayer of the drug  
15 layer may have a low concentration of drug relative to the next sublayer, and  
16 so on, to provide an ascending profile of drug delivery and each sublayer  
17 having a higher concentration of drug than its predecessor is exposed to the  
18 environment of use. Other designs of the dosage form to effect particular  
19 delivery profiles or periods of drug delivery will be apparent to one skilled in  
20 the art.

21 It is preferred that the dosage forms of this invention be administered  
22 when the subject is in the fed state to allow time for maximum swelling of the  
23 polymer matrix prior to the housekeeping wave being initiated. Generally a  
24 meal size that results in a delay of the housekeeping wave of from about 1 to  
25 3 hours is satisfactory. It may be preferable to administer one or more of the  
26 dosage forms at the start of each dosing period, depending on the size of the  
27 dosage form, to facilitate swallowing and yet provide sufficient dose of active  
28 agent. Particularly in those instances where the dosage form is near the  
29 lower end of the size range, i.e., the maximum diameter along the longitudinal  
30 axis is on the order of 7-13 mm, it is preferable that the dosage form be  
31 administered to the subject in the fed state to allow for significant swelling of

[illegible]

Subtotal

FIGs. 5 and 6 show dosage form 10 after a length of time in the fluid environment of the stomach. The polymer matrices have eroded at the exposed surfaces of the matrices, i.e., those portions of the matrices not covered by the insoluble material 18 to such an extent that the device 10 is smaller than its initial swollen configuration. Erosion of the matrices will

1 continue to deliver active agent to the stomach until the dosage form has  
2 substantially eroded so that no significant amount of active agent remains or  
3 has eroded to such an extent that the remainder of the dosage form is  
4 expelled from the stomach. Band 18 will be expelled from the stomach either  
5 alone if it has separated from the dosage form at some time near the end of  
6 the delivery period or as part of the remainder of the dosage form expelled  
7 from the stomach. In some applications, it may be desirable to form band 18  
8 with weakened portions so that band 18 splits and falls away from the  
9 polymer matrices after some predetermined time in the stomach to permit a  
10 particular release pattern of active agent from the dosage form over the  
11 delivery period.

12 The polymer matrices forming layers 12 and 14 and useful in this  
13 invention can be prepared by standard methods from the materials previously  
14 described. The following description will be directed to the active agent layer  
15 14; however, the same procedures may be applied for layer 12 by eliminating  
16 the active agent.

17 Typically, for example, an appropriate quantity of an active agent or  
18 agents and the polymer ingredients are separately passed through a screen,  
19 such as a screen having a mesh of about 40 wires per inch, to reduce any  
20 larger sized materials, and dry mixed. Then, a pharmaceutically-acceptable  
21 liquid, having a sufficient vapor pressure to allow subsequent drying over a  
22 reasonable period of time, for example 24 hours, is added to the dry mixture  
23 and the damp mass is extruded through a mesh screen (e.g. 20 wires per  
24 inch) to further mix the materials. Examples of suitable liquids are water,  
25 methanol, ethanol, isopropanol, acetone, ethyl acetate, and the like. After the  
26 extrusion process, the mixture is allowed to dry, for example in air overnight  
27 at room temperature if the active agent does not require any special handling.  
28 After drying, the resulting material is granulated, for example by passing the  
29 dried material through a mesh screen (e.g., 20 wires per inch). The granules  
30 are combined with a suitable tableting lubricant which has been previously  
31 passed through a mesh screen (e.g., 60 wires per inch). The resulting

1 material is tumbled to produce the finished granulation for the tableting  
2 process. Tablets are produced using well known methodologies associated  
3 with horizontal and vertical compression units using dies and punches of  
4 appropriate dimensions. Alternate granulation methods, for example, fluid  
5 bed granulation or direct compression granulation can be used as well and  
6 such method will be chosen by one skilled in the art depending on the  
7 particular nature of the materials being used and the convenience and  
8 preference of the fabricator. To form the laminated structure of the dosage  
9 form, either the granulated first layer 12 or the second layer 14 is first  
10 compressed in an appropriately sized tableting mold, and then the other  
11 granulated layer is added to the same mold over the compressed layer and  
12 compressed to form the bilayer laminated core.

13 While the foregoing process has been described with respect to dry  
14 ingredients, including the active agent, methodologies for active agents in  
15 other than the solid state can be employed. For example, if the active agent  
16 is not crystalline, but is in liquid form, the active agent may first be  
17 encapsulated as microcapsules to provide a solid that can be fabricated a  
18 described above. Microencapsulation of the liquid active agent can be  
19 accomplished by standard encapsulation techniques including, for example,  
20 spray coating, spray drying encapsulation, centrifugal suspension, and phase  
21 inversion techniques as described in Polymeric Delivery Systems - Properties  
22 and Applications, ACS Symposium Series 520, edited by El-Nokaly, Piatt and  
23 Charpentier (1993), which is incorporated herein by reference. Additionally,  
24 liquid active agents can be absorbed into porous clays and polymers and then  
25 further incorporated into the polymer matrix of the dosage form.

26 In certain applications where it is desirable to dispense an active agent  
27 as a liquid or in a liquid state, it has been found convenient to sorb the liquid,  
28 active agent formulation into porous particles which are then formulated into  
29 the polymer matrix. Materials useful for sorbing the liquid, active agent  
30 formulations are porous particulates that are characterized by high  
31 compressibility or tensile strength to withstand compacting forces applied

2025 RELEASE UNDER E.O. 14176

1 during compacting steps and minimize exudation of liquid, active agent  
2 formulation from the pores; low friability so as to preclude or minimize  
3 exudation of the liquid, active agent formulation from the particles during  
4 compacting steps; and high porosity so as to absorb an adequate amount  
5 of a liquid, active agent formulation to provide an effective amount of active  
6 agent in a dosage form. The particles should be adapted to absorb an  
7 amount of liquid, active agent formulation such that a therapeutically effective  
8 amount of the active agent may be delivered in a unitary dosage form that is  
9 of a size that can be conveniently swallowed by a subject and, preferably  
10 provided in four or fewer tablets or capsules for ingestion at the same time.

11 The porosity of the particles should be such that at least 5% by weight of the  
12 liquid, active agent formulation, based on the total weight of the particle may  
13 be sorbed into the pores of the particles, while the particles exhibit sufficient  
14 strength at such degree of active agent loading so as not to significantly be  
15 crushed or pulverized by compacting forces to which the particles may be  
16 subjected during manufacturing operations. Up to 50% by weight of the  
17 liquid, active agent formulation may be sorbed into crystalline porous  
18 particles, such as calcium hydrogen phosphate, but more typically 30-40%.  
19 Greater amounts of liquid, active agent formulation may be sorbed into the  
20 amorphous particles, such as the magnesium aluminometasilicates.

21 Preferred materials are those having a strength to resist compression  
22 forces of greater than 1500 kg/cm<sup>2</sup> without substantial exudation of the liquid,  
23 active agent formulation, and most preferably without the tablet hardness  
24 plateauing.

25 A particularly suitable porous particle is exemplified by the particular  
26 form of calcium hydrogen phosphate described in U.S. Patent No. 5,486,365,  
27 which is incorporated herein by reference. As described therein, calcium  
28 hydrogen phosphate is prepared by a process yielding a scale-like calcium  
29 hydrogen phosphate that can be represented by the formula  $\text{CaHPO}_4 \cdot m\text{H}_2\text{O}$   
30 wherein  $m$  satisfies the expression  $0 \leq m \leq 2.0$ . The scale-like calcium  
31 hydrogen phosphate produced has characteristic physical properties that


[illegible]

A most preferred form of calcium hydrogen phosphate is that sold under the trademark FujiCalin® by Fuji Chemical Industries (U.S.A.) Inc., Englewood, New Jersey, in types SG and S. Typical parameters for that material include a mean pore size on the order of 70 Angstroms, a mean particle size of about 110 microns, a specific volume of about 2 ml/g, a BET specific surface area of about 30-40 m<sup>2</sup>/g, and an oil and water absorption capacity of about 0.8 ml/g. Type SG typically will have a particle size distribution of 100% through 40 mesh, 60% through 100 mesh and 20% through 200 mesh. Type S typically will have a particle size distribution of 100% through 40 mesh, 90% through 100 mesh and 60% through 200 mesh. Mixtures of the two types may be conveniently employed to provide particulates having physical characteristics that are suitable for various applications, as may be determined by those skilled in the art of pharmaceutical formulation, tableting and manufacturing.

30 The calcium hydrogen phosphate has low friability, demonstrating a  
31 tensile strength of up to about 130 Kg/cm<sup>2</sup> when subjected to compressive

1 forces of up to 3000 Kg/cm<sup>2</sup>. The angle of repose for the preferred materials  
2 typically is on the order of 32-35 degrees.

3 Another material that may be utilized is that formed of magnesium  
4 aluminometasilicate which may be represented by the general formula



7  
8 wherein n satisfies the relationship  $0 \leq n \leq 10$ . Commercially available  
9 magnesium aluminometasilicates are sold as Grades S<sub>1</sub>, SG<sub>1</sub>, UFL<sub>2</sub>, US<sub>2</sub>,  
10 FH<sub>1</sub>, FH<sub>2</sub>, FL<sub>1</sub>, FL<sub>2</sub>, S<sub>2</sub>, SG<sub>2</sub>, NFL<sub>2</sub>N, and NS<sub>2</sub>N, under the trademark Neusilin™  
11 by Fuji Chemical Industries (U.S.A.) Inc., Englewood, New Jersey. Especially  
12 preferred grades are S<sub>1</sub>, SG<sub>1</sub>, US<sub>2</sub> and UFL<sub>2</sub>. Those materials are amorphous  
13 and typically have a specific surface area (arcs) of about 100-300 m<sup>2</sup>/g, an oil  
14 absorption capacity of about 1.3-3.4 ml/g, a mean particle size of about 1-2  
15 microns, an angle of repose about 25° -45°, a specific gravity of about 2 g/ml  
16 and a specific volume of about 2.1-12 ml/g.

17 Other absorptive materials may be substituted for the foregoing. For  
18 example, powders of microcrystalline cellulose sold under the tradenames  
19 Avicel (FMC Corporation) and Elcema (Degussa), porous sodium carboxy  
20 methylcellulose cross-linked sold as Ac-Di-Sol (FMC Corporation), porous soy  
21 bean hull fiber sold under the trade name FI-1 Soy Fiber (Fibred Group), and  
22 porous agglomerated silicon dioxide, sold under the tradenames Cab-O-Sil  
23 (Cabot) and Aerosil (Degussa), may be used.

24 The liquid, active agent formulation may be in any form that can be  
25 dispensed from the inside of the pores as the drug layer disintegrates in the  
26 environment of use. The formulation, for example, may be neat, liquid active  
27 agent, liquid active agent in a solution, suspension, emulsion or self-  
28 emulsifying composition, or the like, or a liposomal solution or solid  
29 formulation, or solid active agent in solution, suspension or slurry. Optionally  
30 other dosage-forming ingredients, such as an anti-oxidant, a suspending  
31 agent, a surface active agent, and the like may be present in the liquid, active

1 agent formulation. The liquid, active agent formulation will be released in a  
2 form most suitable to provide active agent to the site of delivery in a state in  
3 which it may be rapidly absorbed in the environment of use to provide its  
4 beneficial action with minimum delay once delivered to the absorption site.

5 The present invention may have particular utility in the delivery of  
6 liquid, active agent formulations that are in the form of emulsions or self-  
7 emulsifying compositions. The term emulsion as used in this specification  
8 denotes a two-phase system in which one phase is finely dispersed in the  
9 other phase. The term emulsifier, as used by this invention, denotes an agent  
10 that can reduce and/or eliminate the surface and the interfacial tension in a  
11 two-phase system. The emulsifier agent, as used herein, denotes an agent  
12 possessing both hydrophilic and lipophilic groups in the emulsifier agent. The  
13 term microemulsion, as used herein, denotes a multicomponent system that  
14 exhibits a homogenous single phase in which quantities of a drug can be  
15 solubilized. Typically, a microemulsion can be recognized and distinguished  
16 from ordinary emulsions in that the microemulsion is more stable and usually  
17 substantially transparent. The term solution, as used herein, indicates a  
18 chemically and physically homogenous mixture of two or more substances.

19 The emulsion formulations of active agent generally comprise 0.5 wt %  
20 to 99 wt % of a surfactant. The surfactant functions to prevent aggregation,  
21 reduce interfacial tension between constituents, enhance the free-flow of  
22 constituents, and lessen the incidence of constituent retention in the dosage  
23 form. The therapeutic emulsion formulations useful in this invention may  
24 comprise a surfactant that imparts emulsification comprising a member  
25 selected from the group consisting of polyoxyethylenated castor oil  
26 comprising 9 moles of ethylene oxide, polyoxyethylenated castor oil  
27 comprising 15 moles of ethylene oxide, polyoxyethylene castor oil comprising  
28 20 moles of ethylene oxide, polyoxyethylenated castor oil comprising 25  
29 moles of ethylene oxide, polyoxyethylenated castor oil comprising 40 moles of  
30 ethylene oxide, polyoxyethylenated castor oil comprising 52 moles of ethylene  
31 oxide, polyoxyethylenated sorbitan monopalmitate comprising 20 moles of

1 ethylene oxide, polyoxyethylenated sorbitan monolaurate comprising 20  
2 moles of ethylene oxide, polyoxyethylenated sorbitan monolaurate comprising  
3 20 moles of ethylene oxide, polyoxyethylenated sorbitan monooleate  
4 comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan  
5 monostearate comprising 4 moles of ethylene oxide, polyoxyethylenated  
6 sorbitan tristearate comprising 20 moles of ethylene oxide,  
7 polyoxyethylenated sorbitan monostearate comprising 20 moles of ethylene  
8 oxide, polyoxyethylenated sorbitan trioleate comprising 20 moles of ethylene  
9 oxide, polyoxyethylenated stearic acid comprising 8 moles of ethylene oxide,  
10 polyoxyethylene lauryl ether, polyoxyethylenated stearic acid comprising 40  
11 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 50 moles  
12 of ethylene oxide, polyoxyethylenated stearyl alcohol comprising 2 moles of  
13 ethylene oxide, and polyoxyethylenated oleyl alcohol comprising 2 moles of  
14 ethylene oxide. The surfactants are available from Atlas Chemical Industries,  
15 Wilmington, Delaware; Drew Chemical Corp., Boonton, New Jersey; and GAF  
16 Corp., New York, New York.

17 Typically, an active agent emulsified formulation useful in the invention  
18 initially comprises an oil phase. The oil phase of the emulsion comprises any  
19 pharmaceutically acceptable oil which is not miscible with water. The oil can  
20 be an edible liquid such as a non-polar ester of an unsaturated fatty acid,  
21 derivatives of such esters, or mixtures of such esters can be utilized for this  
22 purpose. The oil can be vegetable, mineral, animal or marine in origin.  
23 Examples of non-toxic oils comprise a member selected from the group  
24 consisting of peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, almond  
25 oil, mineral oil, castor oil, coconut oil, palm oil, cocoa butter, safflower, a  
26 mixture of mono- and di- glycerides of 16 to 18 carbon atoms, unsaturated  
27 fatty acids, fractionated triglycerides derived from coconut oil, fractionated  
28 liquid triglycerides derived from short chain 10 to 15 carbon atoms fatty acids,  
29 acetylated monoglycerides, acetylated diglycerides, acetylated triglycerides,  
30 olein known also as glycerol trioleate, palmitin known as glyceryl tripalmitate,  
31 stearin known also as glyceryl tristearate, lauric acid hexylester, oleic acid

Dosage forms of this invention may be utilized to delivery liquid formulations such as contained in immediate-release, commercially-available dosage forms over a prolonged period of time. Examples of commercially available encapsulated liquid formulations that may be utilized include, inter alia, Placidyl® brand of ethchlorvynol, Adalat® brand of nifedipine, VePesid® brand of etoposide, Lanoxicaps® brand of digoxin, Zantac® brand of ranitidine hydrochloride, Sandimmune® and Neoral® brands of cyclosporin, Calderol® brand of calcifediol, Zarontin® brand of ethosuximide, Procardia® brand of nifedipine, Rocaltrol® brand of calcitriol and Vescenoid® brand of tretinoin.

The dosage form may contain an antioxidant to slow or effectively stop the rate of any autoxidizable material present in the dosage form. Representative antioxidants comprise a member selected from the group of ascorbic acid; alpha tocopherol; ascorbyl palmitate; ascorbates; isoascorbates; butylated hydroxyanisole; butylated hydroxytoluene; nordihydroguaiaretic acid; esters of garlic acid comprising at least 3 carbon atoms comprising a member selected from the group consisting of propyl gallate, octyl gallate, decyl gallate, decyl gallate; 6-ethoxy-2,2,4-trimethyl-1,2-dihydro-guoline; N-acetyl-2,6-di-t-butyl-p-aminophenol; butyl tyrosine; 3-tertiarybutyl-4-hydroxyanisole; 2-tertiary-butyl-4-hydroxyanisole; 4-chloro-2,6-ditertiary butyl phenol; 2,6-ditertiary butyl p-methoxy phenol; 2,6-ditertiary

[illegible]

1 butyl-p-cresol; polymeric antioxidants; trihydroxybutyro-phenone  
2 physiologically acceptable salts of ascorbic acid, erythorbic acid, and ascorbyl  
3 acetate; calcium ascorbate; sodium ascorbate; sodium bisulfite; and the like.  
4 The amount of antioxidant used for the present purposes is about 0.001% to  
5 25% of the total weight of the composition present in the dosage form.  
6 Antioxidants are known to the prior art in U.S. Pat. Nos. 2,707,154;  
7 3,573,936; 3,637,772; 4,038,434; 4,186,465 and 4,559,237.

8 The dosage form may also contain a chelating agent to protect the  
9 active agent either during storage or when in use. Examples of chelating  
10 agents include, for example, polyacrylic acid, citric acid, edetic acid, disodium  
11 edetic acid, and the like. The chelating agent may be co-delivered with the  
12 active agent in the environment of use to preserve and protect the active  
13 agent *in situ*. Protection is provided for active agents which are inactivated by  
14 chelation with multivalent metal cations such as calcium, magnesium or  
15 aluminum that may be present in some foods and are at natural background  
16 levels in the fluids of the gastrointestinal tract. Such chelating agents may be  
17 combined with the liquid, active agent formulation in the porous particles, or  
18 the chelating agents may be incorporated into the matrix in which the porous  
19 particles are dispersed.

20 The liquid formulation may also comprise a surfactant or a mixture of  
21 surfactants where the surfactant is selected from the group consisting of  
22 nonionic, anionic and cationic surfactants. Exemplary nontoxic, nonionic  
23 surfactants suitable for forming a composition comprise alkylated aryl  
24 polyether alcohols known as Triton®; polyethylene glycol tertdodecyl throether  
25 available as Nonic®; fatty and amide condensate or Alrosol®; aromatic  
26 polyglycol ether condensate or Neutronyx®; fatty acid alkanolamine or Ninol®  
27 sorbitan monolaurate or Span®; polyoxyethylene sorbitan esters or Tweens®;  
28 sorbitan monolaurate polyoxyethylene or Tween 20®; sorbitan mono-oleate  
29 polyoxyethylene or Tween 80®; triblock copolymers polyoxyethylene-  
30 polyoxypropylene-polyoxyethylene also known as Plurionics®; polyglycolized  
31 glycerides such as Labrasol, PEG-8 glyceryl caprylate/caprate, PEG-4

1 glyceryl caprylate/caprata, polyglyceryl-3 isostearate, PEG-6 glyceryl  
2 monooleate, PEG-6 glyceryl linoleate, PEG-32 palmito stearate, PEG-32  
3 glyceryl stearate, saccharose distearate, saccharose mono-di stearate,  
4 saccharose monoplamitate, glyceryl monolaurate, Imwitors, Softisans and  
5 Dynasans as supplied by Huls America, Somerset, New Jersey,  
6 polyoxyethylated castor oil such as Cremophor and polyoxypropylene-  
7 polyoxyethylene. By way of example, anionic surfactants comprise sulfonic  
8 acids and the salts of sulfonated esters such as sodium lauryl sulfate, sodium  
9 sulfoethyl oleate, dioctyl sodium sulfosuccinate, cetyl sulfate sodium, myristyl  
10 sulfate sodium; sulfated esters; sulfated amides; sulfated alcohols; sulfated  
11 ethers; sulfated carboxylic acids; sulfonated aromatic hydrocarbons;  
12 sulfonated ethers; and the like. The cationic surface active agents comprise  
13 cetyl pyridinium chloride; cetyl trimethyl ammonium bromide; diethylmethyl  
14 cetyl ammonium chloride; benzalkonium chloride; benzethonium chloride;  
15 primary alkylammonium salts; secondary alkylammonium salts; tertiary  
16 alkylammonium salts; quaternary alkylammonium salts; acylated polyamines;  
17 salts of heterocyclic amines; palmitoyl carnitine chloride, behentriammonium  
18 methosulfate, and the like. Generally, from 0.01 part to 1000 parts by weight  
19 of surfactant, per 100 parts of active agent is admixed with the active agent to  
20 provide the active agent formulation. Surfactants are known to the prior art in  
21 U.S. Pat. Nos. 2,805,977; and in 4,182,330.

22 The liquid formulation may comprise permeation enhancers that  
23 facilitate absorption of the active agent in the environment of use. Such  
24 enhancers may, for example, open the so-called "tight junctions" in the  
25 gastrointestinal tract or modify the effect of cellular components, such a p-  
26 glycoprotein and the like. Suitable enhancers include alkali metal salts of  
27 salicylic acid, such as sodium salicylate, caprylic or capric acid, such as  
28 sodium caprylate or sodium caprate, diethylene glycol monoethyl ether,  
29 propylene glycol laurate, and the like. Enhancers may include the bile salts,  
30 such as sodium deoxycholate. Various p-glycoprotein modulators are  
31 described in US Patents 5,112,817 and 5,643,909, which are incorporated

1 herein by reference. Various other absorption enhancing compounds and  
2 materials are described in US Patent 5,824,638, which also is incorporated  
3 herein by reference. Enhancers may be used either alone or as mixtures in  
4 combination with other enhancers.

5 The liquid, active agent formulation of the dosage form may optionally  
6 be formulated with inorganic or organic acids or salts of drugs which promote  
7 dissolution and disintegration or swelling of the porous particles upon contact  
8 with biological fluids. The acids serve to lower the pH of the  
9 microenvironment at the porous particle, and promote rapid dissolution of a  
10 particle, such as calcium hydrogen phosphate, that is soluble in low pH  
11 environments, thus providing rapid liberation of the liquid, active agent  
12 formulation contained in the porous particle. Examples of organic acids  
13 include citric acid, tartaric acid, succinic acid, malic acid, fumaric acid and the  
14 like. Salts of drugs where the anion of the salt is acidic, such as acetate,  
15 hydrochloride, hydrobromide, sulfate, succinate, citrate, and the like, can be  
16 utilized to produce immediate disintegration and dissolution of the porous  
17 particle. A more complete list of acidic components for this application is  
18 provided in Journal of Pharmaceutical Sciences, "Pharmaceutical Salts",  
19 Review Articles, January, (1977), Vol. 66, No. 1, pages 1-19. The interaction  
20 of an acidic component with a porous particle of, for example, calcium  
21 hydrogen phosphate, in the presence of water from gastric fluids accelerates  
22 dissolution of the particle at a greater rate than gastric fluid alone, producing a  
23 more rapid and complete release of the liquid, active agent formulation into  
24 the environment of use. Likewise alkaline components or salts of drugs  
25 where the cation of the salt is alkaline such as choline may be incorporated  
26 into the liquid, active agent formulation to promote rapid and complete  
27 dissolution of a porous particle which is soluble or swells at elevated pH.  
28 Such a particle may be formed, for example, of poly(methacrylic acid-methyl  
29 methacrylate) 1:2 available commercially as Eudragit S100 (Rohm America,  
30 Somerset, New Jersey).

31 In order to prepare a dosage form of the present invention, the first

1 layer 12 typically is prepared by granulation and tableting methods described  
2 previously and which are conventionally described in Remington's  
3 Pharmaceutical Sciences, Eighteenth Edition (1990). Then, the active agent  
4 layer 14 is prepared and laminated onto layer 12, to provide a dosage form of  
5 the desired size and shape. In its initial prepared form, the dosage form is  
6 about the size and dimensions of a size "000" to size 5 hard gelatin capsule.  
7 The cross-sectional shape of the matrix may be circular or may be oval,  
8 triangular, square, hexagonal or other shapes that are easily handled,  
9 especially by patients with limited dexterity. Presently preferred shapes are  
10 those in which the cross-section is circular or oval. The bands are then  
11 placed onto the surface of active agent formulation matrix or printed onto the  
12 surface using conventional banding or printing techniques, such as disclosed  
13 herein or in U.S. Patent 5,534,263, which is incorporated herein by reference.

14 As described above, the active agent itself may be in liquid, solid or  
15 semisolid form. The active agent formulation may contain additional materials  
16 and may be designed in a multitude of ways to provide a specific active agent  
17 delivery profile. In one embodiment the active agent is capable of slow  
18 dispersion or dissolution in the stomach. In another embodiment, the polymer  
19 matrix of layer 14 may contain a surfactant so that the formulation is more  
20 readily susceptible to erosion in the stomach. In still another embodiment, the  
21 formulation of layer 14 may include a solid surfactant and provide active  
22 agent delivery in a finely dispersed form. In yet another embodiment,  
23 formulation layer 14 may include a lipidic or wax matrix that erodes as the  
24 active agent is released. In yet a further embodiment, the formulation may  
25 include coated microspheres of an active agent or microspheres of an active  
26 agent and an adjuvant. The active agent either alone or with adjuvant can be  
27 delivered simultaneously from the microspheres either by diffusion or by  
28 osmosis. Suitable materials useful as active agent carriers and excipients are  
29 known in the art and are disclosed in U.S. Patents Nos. 4,595,583 and  
30 4,874,388, for example. For active agents that may tend to degrade in the  
31 stomach, the active agent can be enterically coated to protect the active

1 agent it passes to the small intestine in accordance with conventional coating  
2 methods.

3 The dispensing devices of the invention find use, for example, in  
4 humans or other animals. The environment of use is a fluid environment and  
5 for the purposes of this invention primarily includes the fluid environment of  
6 the stomach and the upper intestinal tract or small intestine. A single  
7 dispensing device or several dispensing devices can be administered to a  
8 subject during a therapeutic program.

9 The terms "active agent" and "drug" are used interchangeably herein  
10 and refer to an agent, active agent, compound, composition of matter or  
11 mixture thereof which provides some pharmacologic, often beneficial, effect.  
12 This includes foods, food supplements, nutrients, drugs, antacids, vitamins  
13 such as, for example, Vitamin C, Vitamin E, microorganism attenuators and  
14 other agents that benefit the environment of use. As used herein, the terms  
15 include any physiologically or pharmacologically active substance that  
16 produces a localized or systemic effect or effects in animals, including warm  
17 blooded mammals, humans and primates; domestic household or farm  
18 animals such as cats, dogs, sheep, goats, cattle, horses and pigs; laboratory  
19 animals such as mice, rats and guinea pigs; zoo and wild animals; and the  
20 like. The active agent that can be delivered includes inorganic and organic  
21 compounds, including, without limitation, active agents which act on the  
22 peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal  
23 muscles, the cardiovascular system, smooth muscles, the blood circulatory  
24 system, synaptic sites, neuroeffector junctional sites, endocrine and hormone  
25 systems, the immunological system, the reproductive system, the skeletal  
26 system, autacoid systems, the alimentary and excretory systems, the  
27 histamine system and the central nervous system.

28 Suitable active agents may be selected from, for example, proteins,  
29 enzymes, enzyme inhibitors, hormones, polynucleotides, nucleoproteins,  
30 polysaccharides, glycoproteins, lipoproteins, peptides, polypeptides, steroids,  
31 hypnotics and sedatives, psychic energizers, tranquilizers, anticonvulsants,

1 antidepressants, muscle relaxants, antiparkinson agents, analgesics,  
2 immunosuppressants, anti-inflammatories, antihistamines, local anesthetics,  
3 muscle contractants, antimicrobials, antimalarials, antivirals, antibiotics,  
4 antiobesity agents, antidiabetic agents, hormonal agents including  
5 contraceptives, sympathomimetics, polypeptides and proteins capable of  
6 eliciting physiological effects, diuretics, lipid regulating agents, antiandrogenic  
7 agents, antiparasitics, neoplastics, antineoplastics, antihyperglycemics,  
8 hypoglycemics, nutritional agents and supplements, growth supplements,  
9 fats, ophthalmics, antienteritis agents, electrolytes and diagnostic agents.

10       Examples of active agents useful in this invention include  
11 prochlorperazine edisylate, ferrous sulfate, albuterol, aminocaproic acid,  
12 mecamlamine hydrochloride, procainamide hydrochloride, amphetamine  
13 sulfate, methamphetamine hydrochloride, benzphetamine hydrochloride,  
14 isoproterenol sulfate, phenmetrazine hydrochloride, bethanechol chloride,  
15 methacholine chloride, pilocarpine hydrochloride, atropine sulfate,  
16 scopolamine bromide, isopropamide iodide, tridihexethyl chloride, phenformin  
17 hydrochloride, metformin, methylphenidate hydrochloride, acrivastine,  
18 benazepril, carbamazepine, chlorothiazide, desmopressin, dicumarol,  
19 furosemide, gepirone, griseofulvin, levodopa/benserazide, lithium,  
20 methylphenidate, 8-methoxalen, metoprolol, misoprostol, octreotide,  
21 phenobarbital, phenytoin, piretanide, paraestatin, propoxyphen, riboflavin,  
22 sertaline, spironolactone, sumatriptan, ticlopidine, theophylline choline,  
23 cephalexin hydrochloride, diphenidol, meclizine hydrochloride,  
24 prochlorperazine maleate, phenoxybenzamine, thiethylperazine maleate,  
25 anisindione, diphenadione erythryl tetranitrate, digoxin, isofluorophate,  
26 acetazolamide, nifedipine, methazolamide, bendroflumethiazide,  
27 chlorpropamide, glipizide, glyburide, glimepiride, tolbutamide, chlorpropamide, ,  
28 acetohexamide, troglitazone, orlistat, bupropion, nefazodone, tolazamide,  
29 chlormadinone acetate, phenaglycodol, allopurinol, aluminum aspirin,  
30 methotrexate, acetyl sulfisoxazole, hydrocortisone, hydrocorticosterone  
31 acetate, cortisone acetate, dexamethasone and its derivatives such as

29           The present invention is particularly useful to deliver active agents that  
30   are poorly absorbed in the lower gastrointestinal tract, but well absorbed in  
31   the upper gastrointestinal tract (i.e., the small intestine) or active agents that

1 exhibit poor solubility such that the increased retention time in the stomach  
2 allows for a greater quantity of active agent to dissolve from the dosage form  
3 than would otherwise be dissolved. Typically, antiviral, antifungal and  
4 antibiotic agents, e.g. sulfonamides, quinolones, penicillins, cephalosporins,  
5 aminoglycosides, and tetracyclines, are representative classes of agents for  
6 which the invention is particularly useful. Such antibiotic agents may include,  
7 for example,  $\beta$ -lactam antibiotics, vancomycin, clidamycin, erthromycin,  
8 clarithromycin, 14-hydroxy clarithromycin, azithromycin, roxithromycin,  
9 dirithromycin, trimethoprim-sulfamethoxazole, rifampin, ciprofloxacin,  
10 amoxicillin, clindamycin, ceftriaxone, cefotaxime, chloramphenicol,  
11 clindamycin, cefoxitin, doxycycline, spectinomycin, ofloxacin, rifampin,  
12 minocycline, doxycycline, aztreonam, imipenem, meropenem, nitrofurantoin,  
13 azithromycin, atovaquone, trimetrexate, dapsone, primaquin, trimetrexate,  
14 ketoconazole, fluconazole, amphotericin B, itraconazole, trifluridine,  
15 foscarnet, zidovudine, amantadine, interferon alfa, sulfonamides such as  
16 sulfisoxazole, sulfadiazine, and sulfasalazine, quinolones and  
17 fluoroquinolones such as, for example, cinoxacin, ofloxacin, diprofloxacin,  
18 ofloxacin, sparfloxacin, lomefloxacin, fleroxacin, pefloxacin and amifloxacin,  
19 gentamicin, tobramycin, amikacin, netilmicin, kanamycin, and neomycin.  
20 Representative antiviral agents include acyclovir, famciclovir, foscarnet,  
21 ganciclovir, ritonavir, idoxuridine, sorivudine, trifluridine, valacyclovir,  
22 vidarabine, didanosine, stavudine, zalcitabine, zidovudine, amantadine,  
23 interferons, e.g., interferon alpha, ribavirin, rimantadine, nucleoside RT  
24 inhibitors, such as lamivudine and adefovir, non-nucleoside inhibitors such  
25 as nevirapine, delavairidine, zalcitabine, saquinavir and indinavir, nucleoside  
26 DNAP inhibitors such as famciclovir, fialuridine, cidofovir and lobucavir,  
27 antisense oligonucleotides such as afovirsen, receptor decoys such as  
28 SICAM-1, capsid binding agents such as pirodavir, and neuraminidase  
29 inhibitors such as GG167.

30 Specific examples of active agents that are readily absorbed in the  
31 upper gastrointestinal tract relative to the lower gastrointestinal tract are

1 acyclovir, ganciclovir, cimetidine, ranitidine, captopril, methyldopa, selegiline  
2 and the like. Specific examples of active agents that exhibit poor solubility in  
3 water are diphenidol, meclizine hydrochloride, hydralazine, prochlorperazine  
4 maleate, phenoxybenzamine, triethylperazine maleate, anisindone,  
5 diphenadione erythryl tetranitrate, digoxin, isoflurophate, acetazolamide,  
6 methazolamide, bendroflumethiazide, chlorpropamide, tolazamide,  
7 chlormadionone acetate, phenaglycodol, allopurinol, aluminum aspirin,  
8 methotrexate, acetyl sulfisoxazole, erythromycin, progestins, estrogenic,  
9 progestational corticosteroids, hydrocortisone, hydrocortisone acetate,  
10 cortisone acetate, tramcinolone, methyltestosterone, 17-beta-estradiol, ethinyl  
11 estradiol, prazosin hydrochloride, ethinyl estradiol 3-methyl ether,  
12 prednisolone, 17-alpha-hydroxyprogesterone acetate, 19-norprogesterone,  
13 norgestrel, norethindrone, progesterone, norgestronone, norethynodrel, and  
14 the like.

15 Retention of the device of the present invention in the stomach for a  
16 prolonged period of time make it especially useful for the localized treatment  
17 of gastric acidity and gastrointestinal disorders such as duodenal ulcers,  
18 peptic ulcers and chronic gastritis, particularly those resulting from the  
19 presence of *Helicobacter pylori*. Representative active agents for such uses  
20 include cimetidine, ranitidine, famotidine, nizatidine, zolentidine, omeprazole,  
21 lansoprazole and active agents useful for the treatment of *Helicobacter pylori*,  
22 such as metronidazole, tinidazole, amoxicillin, clarithromycin, minocycline  
23 and tetracycline.

24 While for reasons of efficacy, safety, economy, convenience and/or  
25 efficiency it may be desirable to utilize a single active agent in the active  
26 agent formulation, it is to be understood that more than one active agent may  
27 be incorporated into the active agent formulation in a device of this invention,  
28 and that the use of the term "agent" or "active agent" in no way excludes the  
29 use of two or more such agents or active agents. The agents can be in  
30 various forms, such as uncharged molecules, components of molecular  
31 complexes or nonirritating, pharmacologically acceptable salts. Also, simple

1 derivatives of the agents (such as prodrugs, ethers, esters, amides, etc)  
2 which are easily hydrolyzed by body pH, enzymes, etc, can be employed.  
3 Combinations of two or more active agents can optionally be co-delivered,  
4 simultaneously or sequentially from the dosage form of this invention. For  
5 simultaneous delivery of two or more active agents, the active agents will  
6 typically be uniformly dispersed throughout the dosage form. For sequential  
7 delivery, different active agents can be selectively placed within the dosage  
8 form during its manufacture, as by using the multilaminate structure for layer  
9 14 described previously. Alternatively, a core that contains one active agent  
10 can be prepared, and the core coated or formed with an outer layer  
11 containing a second active agent. Initially, the agent in the outer portion of  
12 the dosage form will be dispensed, and as the dosage form erodes in the  
13 stomach, the second active agent will be dispensed at a later time.

*Sub a2*  
15 The active agent dosage form may include additional ingredients, such  
16 as, for example, a buffer or other agents for controlling pH in the stomach or  
17 elsewhere in the gastrointestinal tract, an agent or agents for delaying onset  
18 of the housekeeping wave, preferably locally delivered by the dosage form in  
19 amounts not resulting in any substantial systemic effect to the subject, as for  
20 example, anticholinergic agents such as propantheline, and other agents  
21 including, but not limited to, methylcellulose, guar gum, fats such as  
22 triglyceride esters, e.g., triethanol myristate, fatty acids of 10-15 carbon  
23 atoms, and the like, a viscosity regulating vehicle, a surfactant, a dye, a  
24 permeation enhancer, a proteinase inhibitor, or other formulation ingredients  
25 and additives, as are known in the art. The active agent dosage form may  
26 also include minor amounts of polymers which serve useful functions in tablet  
27 formation, for example, to improve the tablet cohesiveness after compression  
28 or to improve the physical or chemical stability of the dosage form. These  
29 polymers are added at quantities less than 10% by weight and preferably less  
30 than 5% by weight of the tablet. Examples of such polymers include  
31 hydroxypropyl methyl cellulose having molecular weights of less than 20,000  
grams per mole, methylcellulose having a molecular weight of less than

1 20,000 grams per mole, polyvinyl pyrrolidone having a molecular weight of  
2 less than 360,000 grams per mole, and the like.

3 The amount of active agent employed in the delivery device will be that  
4 amount necessary to deliver a therapeutically effective amount of the agent to  
5 achieve the desired therapeutic result, and may range from 1 ng to 2500 mg,  
6 although lower and higher amounts may be used in particular circumstances.  
7 In practice, this will vary widely depending upon the particular agent, the  
8 degree of active agent absorption, the severity of the condition, and the  
9 desired therapeutic effect. Thus, it is not practical to define a particular range  
10 for the therapeutically effective amount of each active agent incorporated into  
11 the device. Such ranges can easily be determined by one skilled in the art  
12 using conventional methods, for example from dose ranging and plasma level  
13 studies. Any references to specific quantities of active agent or specific dose  
14 ranges of active agent herein are intended to include the amount or amounts  
15 of active agent specified and bioequivalents thereof.

16 When the delivery device of this invention is being used to substitute  
17 for one or more doses of an active agent presented in a conventional dosage  
18 form that is usually prescribed for multiple dosing during a predetermined  
19 period, the sum of the amounts of active agent present in the multiple doses  
20 of the conventional dosage form for use in the period may be used to  
21 determine an upper limit on the of the amount of active agent to be included  
22 in the device of this invention. For example, if the conventional dosage form  
23 contains 200 mg of active agent and is to be administered every 3 hours, a  
24 dosage form of this invention may be prepared for administration every 6  
25 hours, and that dosage form may contain 400 mg of active agent which will be  
26 delivered over the 6 hour period.

27 However, when compliance with multiple dosing is a problem, the  
28 advantage of administering the dosage forms of the invention at fewer times  
29 throughout a twenty-four hour period may provide incentive to incorporate  
30 greater amounts of active agent, where such greater amounts do not have  
31 any deleterious effects. The specific amount of active agent to be included in

1 the dosage form of the invention can easily be determined by routine dosage  
2 studies that compare the blood plasma active agent levels of subjects with  
3 conventional dosing and the dosage form of this invention.

4 The dosage forms of this invention can conveniently release active  
5 agent in a controlled and sustained manner over a prolonged period.  
6 Typically, active agent will be released from the dosage form at a rate that  
7 releases a therapeutically effective amount of active agent to the subject over  
8 a substantial portion of the period between administration of the dosage  
9 forms. Typically, release will occur over 40% of the period between repeated  
10 administration of the dosage form, more preferably at least over 60% of the  
11 period, and most preferably over 80% of the period. Dosage forms that result  
12 in a  $C_{max}$  of the active agent in the plasma of the subject being reached within  
13 1-2 hours, and maintained for a prolonged period, preferably, 4-6 hours, may  
14 be particularly useful.

15 In an especially preferred embodiment, the invention comprises a first  
16 layer 12 having a composition of 60-100 percent of a water soluble,  
17 polyethylene oxide polymer having a molecular weight between about  
18 900,000 and 10,000,000, and a drug layer 14 having from about 10 weight  
19 percent to about 50 weight percent of a water-soluble polyethylene oxide  
20 polymer having a molecular weight between about 100,000 and 600,000 and  
21 from about 10 weight percent to about 60 weight percent of a water-insoluble  
22 hydroxypropyl cellulose polymer. The hydroxypropyl cellulose polymer  
23 preferably has a hydroxypropyl content of between about 8-15 weight  
24 percent, and most preferably between about 10-13 weight percent. The  
25 composition of this invention is useful to prepare the active agent dosage  
26 forms described herein, and finds particular utility with respect to the antiviral,  
27 antimicrobial, antidiabetic, antihyperglycemic, hypoglycemic, antidepressant,  
28 antiobesity, and antifungal active agents described herein.

29 The following examples are illustrative of the present invention. They  
30 are not to be construed as limiting the scope of the invention. Variations and  
31 equivalents of these examples will be apparent to those skilled in the art in

1 light of the present disclosure, the drawings and the claims herein. In  
2 particular, variations in the dosage forms described that are bioequivalent are  
3 considered within the scope of the present invention.

#### 4 PREPARATION 1

5  
6  
7 An example of a active agent which requires frequent dosing is  
8 acyclovir. A typical dosing regimen for this antiviral active agent is five doses  
9 per day administered every four hours. A dosage form in accordance with  
10 this invention for twice daily dosing of acyclovir is formulated according to the  
11 following procedures. The dosage form is retained in the stomach and  
12 releases acyclovir over a prolonged period of time.

13  
14 22.5 Grams of acyclovir and 3.6 grams of the gel-forming polymer  
15 polyethylene oxide, having a number average molecular weight of  
16 approximately 200,000 grams per mole, are separately screened through a  
17 mesh having 40 wires per inch. The polyethylene oxide is supplied under the  
18 trade name Polyox® grade WSR N80 as manufactured by Union Carbide  
19 Corporation, Danbury, Connecticut. The sized active agent and polymer are  
20 dry mixed. Then, 3.75 grams of a hydroattractant water-insoluble polymer,  
21 hydroxypropyl cellulose having a hydroxypropyl content of 10-13 weight  
22 percent and an average fiber particle size of 50 microns, is sieved through the  
23 40-mesh screen and blended into the mixture. The hydroxypropyl cellulose is  
24 supplied as Low-Substituted Hydroxypropyl Cellulose grade 11 as  
25 manufactured by Shin-Etsu Chemical Company, Ltd., Tokyo, Japan.  
26 Anhydrous ethyl alcohol, specially denatured formula 3A, i.e., ethanol  
27 denatured with 5 volume percent methanol, is added to the mixture with  
28 stirring until a uniformly damp mass formed. This damp mass is extruded with  
29 pressure through a screen having 20 wires per inch. The extrudate is then  
30 allowed to air dry at room temperature overnight. After drying, the resulting  
31 extrudate is passed again through the 20-mesh sieve, forming granules. 0.15  
32 Grams of the tableting lubricant, magnesium stearate, are passed through a

1 sieve having 60 wires per inch. The sized 60-mesh lubricant is then tumbled  
2 into the granules to produce the finished drug layer granulation.

3 A separate granulation is prepared by passing 29.85 grams of a  
4 different gel-forming polyethylene oxide through a mesh having 20 wires per  
5 inch. The polyethylene oxide has a molecular weight of approximately 7  
6 million and is supplied as Polyox grade WSR-303. 0.15 Grams of magnesium  
7 stearate sized through a 60 mesh screen is tumbled into the 20 mesh Polyox  
8 303, to produce the finished retention-layer granulation.

9 800 Milligram portions of the resulting drug layer granulation and 250  
10 mg portions of the retention-layer granulation are weighed and compacted  
11 with caplet-shaped tooling on a Carver press at pressure head of 1.5 tons to a  
12 target tablet weight, e.g., each approximately 1050 mg. The shape of the  
13 tablet has approximately cylindrical proportions, for example, the diameter is  
14 approximately 7.6 millimeters (mm) and the length approximately 22 mm.  
15 Such dosage form contains a unit dose of 600 mg acyclovir.

16 A tube of polyolefin material having an outside diameter of 7.7 mm and  
17 having a wall thickness of 0.25 mm is sliced with a razor to produce rings.  
18 The width of each ring was approximately 3 mm. One ring is then press fitted  
19 onto each caplet such that the ring, or band, is located approximately at the  
20 midpoint of the length of the caplet. This step completes the fabrication  
21 procedure of the acyclovir banded caplet. The acyclovir dosage forms  
22 prepared as above are retained in the stomach and release acyclovir over a  
23 prolonged period.

#### 24 25 EXAMPLE 1 (ASSAY)

26 Banded devices fabricated in Preparation 1 are assayed for  
27 dimensional changes and release of active agent as follows:

28 A banded dosage form is placed in a beaker of simulated gastric fluid,  
29 as specified in U.S. Pharmacopedia/National Formulary 23/18, having a pH of  
30 approximately 1.4 and a maintained temperature of 37° C. After one hour,  
31 the device is removed and measured for dimensional change in length and

1 diameter. The swollen device will have the general appearance of the  
2 dosage form shown in Figure 4.

3 Samples of the dosage form are tested for release of active agent by  
4 shaking at prescribed conditions in an aqueous media simulating the media in  
5 the upper gastrointestinal tract. Each dosage form is first placed in a  
6 cylindrical, slotted basket having inside diameter of 15 mm and inside length  
7 of 52 mm. Each basket has eight slots and each slot is 1-2 mm wide and 52  
8 mm long and positioned lengthwise along the length of the basket. The  
9 basket containing the dosage form is then placed in 50 milliliters of simulated  
10 gastric fluid and shaken at a frequency of 100 cycles per minutes at an  
11 amplitude of 3.7 cm for one hour. Then, the baskets containing the dosage  
12 forms are transferred to another set of receptacles having the same fluid  
13 media composition and volume as above and shaken for another hour. This  
14 procedure is continued until the number of desired 50 ml release receptor  
15 samples representing the number of hours of release are accumulated. After  
16 the collective number of hours, each basket is transferred to a fresh, single 50  
17 ml receptor where it is then shaken for an additional 3 hours. This completes  
18 the testing period. The concentration of active agent in the resulting  
19 receptors is then analyzed by using ultraviolet spectrometry assay at a  
20 wavelength specific for the active agent being tested. The release of active  
21 agent as a function of time, e.g. release rate (mg/hour), cumulative release  
22 (mg), and time for 90% release of active agent ( $T_{90}$ ) are determined.

#### 23 24 EXAMPLE 2

25 Dosage forms of this invention containing the antiviral drug ganciclovir  
26 are prepared in accordance with the procedures of Preparation 1. The  
27 dosage forms prepared are retained in the stomach and release ganciclovir  
28 over a prolonged period of time.

#### 29 30 EXAMPLE 3

31 Equivalent amounts of the following polymers are substituted for the

1 polyethylene oxide in the retention-layer in Preparation 1 (all molecular  
2 weights are number average molecular weights in grams per mole):  
3 hydroxypropyl cellulose (MW: 1,000,000), hydroxypropyl methyl cellulose  
4 (MW: 254,000), hydroxyethyl cellulose (MW: 1,300,000), sodium carboxy  
5 methylcellulose (MW: 700,000), calcium carboxymethyl cellulose (MW:  
6 700,000), methyl cellulose (MW: 135,000), and polyvinyl alcohol (Elvanol®  
7 HV), and dosage forms with a polyethylene band are fabricated to the same  
8 dimensions as described in Preparation 1 with equivalent quantities of the  
9 active agents acyclovir and ganciclovir. The prepared dosage forms are  
10 retained in the stomach of a subject for a prolonged period and deliver the  
11 antiviral active agents ganciclovir and acyclovir over a prolonged period of  
12 time.

#### 13 14 EXAMPLE 4

15 Dosage forms containing equivalent quantities of the antiviral drugs  
16 acyclovir and ganciclovir are prepared according to the procedures in  
17 Preparation 1, except that the nonwater soluble hydroattractant used is,  
18 respectively, microcrystalline cellulose (Avicel), cross-linked sodium or  
19 calcium carboxymethyl cellulose, cellulose fiber (Solka-Floc, Arbocel,  
20 Elcema), cross-linked polyvinyl pyrrolidone (Polyplasdone XL), cross-linked  
21 Amberlite resin, alginates (Satialgine), colloidal magnesium-aluminum silicate  
22 (Veegum), corn starch granules, rice starch granules, potato starch granules,  
23 and sodium carboxymethyl starch (Expotab, Primojel). The prepared dosage  
24 forms are retained in the stomach of a subject and deliver active agent over a  
25 prolonged period of time.

#### 26 27 EXAMPLE 5

28 The following active agents are substituted, in the quantities indicated  
29 in the parentheses following each active agent listed, for the quantity of  
30 acyclovir in Preparation 1: cimetidine (400 mg; 800 mg, 1200 mg, 1600 mg),  
31 ranitidine (150 mg; 200 mg, 300 mg), captopril (12.5 mg; 25 mg; 50 mg; 100

1 mg, 150 mg), methyldopa (125; 250; 500 mg), and selegiline (5 mg, 10 mg)  
2 and the dosage forms are prepared in the same manner as described in  
3 Preparation 1. The prepared dosage forms are retained in the stomach of a  
4 subject and deliver active agent over a prolonged period of time.

#### 6 EXAMPLE 6

7 Dosage forms of this invention containing 600 mg of acyclovir are  
8 fabricated according to the procedures of Preparation 1, except that the tablet  
9 is inserted into a size "00" hard gelatin capsule before banding. The band is  
10 applied by a printing process using the methods and compositions described  
11 in U.S. Patent 5,534,263, incorporated herein by reference, where the band  
12 material is ethyl acrylate/methyl methacrylate 70:30 copolymer applied as an  
13 aqueous latex (Eudragit NE 30 D, Rohm Tech). The banding material may be  
14 formulated with 30% by weight of a plasticizer, such as triacetin. Optionally,  
15 an amount of organic solvent such as ethyl alcohol or isopropyl alcohol may  
16 be blended into the aqueous latex to promote good band formation and rapid  
17 drying of the latex after application. The resulting dosage forms are smooth  
18 and easy to swallow.

#### 21 EXAMPLE 7

22 A gastric platform dosage form of the antihistamine drug, fexofenadine  
23 hydrochloride, is prepared according to the following procedures. The active  
24 agent layer is prepared from 11.5 grams of the drug, 30 grams of  
25 polyethylene oxide, 54 grams of low-substituted hydroxypropyl cellulose, and  
26 3.7 grams of polyvinyl pyrrolidone by individually passing those materials  
27 through a sieve having 40 wires per inch, and then tumble mixing the three  
28 components together for 10 minutes. The polyethylene oxide (Polyox® WSR-  
29 N-60K as supplied by Union Carbide, Danbury, Connecticut) has a molecular  
30 weight of approximately 2 million grams per mole, the polyvinyl pyrrolidone  
31 (Povidone® K2932 as supplied by GAF Corporation, New York, New York)  
32 has a molecular weight of approximately 45,000 grams per mole and the

[illegible]

Individual portions of the drug granulation weighing approximately 522 mg and of the highly swellable, retention layer granulation weighing approximately 522 mg each are separately compressed with size 0 caplet tooling on a Carver press with a force of about 1.5 tons to form a bilayer, laminated tablet core. Each tablet contains about 120 mg of fexofenadine hydrochloride.

A solution for use in film coating the tablets is then prepared by stirring 40 grams of methyl cellulose (Methocel A15 LV Premium supplied by Dow Chemical, Midland Michigan) and 10 grams of sorbitol in 950 grams of purified water at room temperature. The mixture is chilled overnight at 9° centigrade to complete dissolution. The tablets from above are then transferred to a pharmaceutical coating pan, and spray coated with the solution in a current of warmed air until a dry film coating weight of about 37

1 mg is deposited onto each tablet. The film coated tablet cores are then dried  
2 in a forced air oven at 40 degrees Centigrade overnight.

3 An aqueous dispersion for use in banding the tablets is prepared by  
4 dissolving 30 grams of triacetin in 174.75 grams of ethyl acrylate  
5 methylmethacrylate 70:30 copolymer aqueous dispersion (Eudragit® NE40D  
6 supplied by Rohm Corporation, Darmstadt, West Germany). Then, 0.1  
7 grams of anti-foam agent ( Simethicone Q7-2587, Dow Chemical, Midland,  
8 Michigan) is blended into the mixture. This forms the final composition of the  
9 banding dispersion.

10 The dried film coated tablets from above are then banded by applying  
11 the above banding dispersion in a transfer printing process using a printing  
12 wheel having a width of approximately 100 mils (2.54 mm). The freshly  
13 banded system is then dried in warm air to remove the water from the  
14 aqueous dispersion, leaving a single band located in the center of the caplet  
15 having a width of approximately 120 mils (3.05 mm) and a weight of  
16 approximately 21 mg. The entire banded system is then overcoated with  
17 more of the aqueous-based film coat solution using the formulation and  
18 process as described above until a film coat weight of about 31 mg is applied.  
19 This completes fabrication of the dosage form.

## 20 21 EXAMPLE 8

22 A gastric platform dosage form delivering the antibiotic, minocycline,  
23 for treatment of Helicobacter pylori gastritis, gastric and duodenal ulcers, with  
24 a single core layer is fabricated and compared to a bilayer core system of this  
25 invention. The procedures for fabrication are similar to those specified in  
26 EXAMPLE 7. For the single layer dosage form, 17.8 grams of minocycline  
27 hydrochloride, 24.6 grams of polyethylene oxide 53.8 grams of low-substituted  
28 hydroxypropyl cellulose, 3 grams of polyvinyl pyrrolidone 0.3 grams of  
29 colloidal silicon dioxide, and 0.5 grams of magnesium stearate are granulated  
30 according to the procedures in EXAMPLE 7. The excipients are the same as  
31 in this example except the polyethylene oxide had a molecular weight of

1 approximately 4 million grams per mole (Polyox WSR 301). The granulation  
2 is compressed into caplets weighing approximately 1042 mg where each  
3 tablet contains a unit dose of about 185 mg of minocycline hydrochloride.  
4 The tablets are film subcoated with a coating weight of 52 mg , banded with a  
5 21 mg band, and overcoated with 21 mg of film. The compositions of the  
6 subcoat, band, and overcoat are the same as disclosed in EXAMPLE 7.

7 The bilayer dosage form is prepared using the granulation procedures  
8 of EXAMPLE 7. 35.4 Grams of minocycline hydrochloride, 22.0 grams of  
9 Polyox WSR-301, 39 grams of low-substituted hydroxypropyl cellulose, 2.8  
10 grams of polyvinyl pyrrolidone K2932 are wet granulated. 0.3 Grams of  
11 Aerosil silicon dioxide and 0.5 grams of magnesium stearate are dry mixed  
12 into the blend, producing the finished drug layer granulation. The retention  
13 layer is prepared by passing 80 grams of Polyox WSR-303 and 20 grams of  
14 powdered cellulose Solka Floc 900 (Fiber Sales and Development  
15 Corporation, Urbana, Ohio) through a 40 mesh screen and the components  
16 are tumbled mixed for about 10 minutes. Denatured ethanol formula 3A is  
17 added with stirring to form a uniform damp mass, which is then forced through  
18 a 20 mesh sieve. The resulting granules are air dried overnight, then passed  
19 again through the 20 mesh sieve, producing the high-swelling, retention layer  
20 granulation. Then, the drug layer granulation and the retention layer  
21 granulation are compressed into biayer caplets consisting of a drug layer of  
22 522 mg and a retention layer of 522 mg. The bilayer tablets are film coated  
23 and banded according to the compositions and procedures described in  
24 EXAMPLE 7. Each dosage form, i.e., bilayer tablet, contained 185 mg of  
25 minocycline hydrochloride.

26 The resulting single layer and bilayer dosage forms are compared in  
27 vivo as follows: A single layer dosage form is administered to each of three  
28 dogs in the fed state. Plasma samples are collected periodically over the 48-  
29 hour period post dosing. The concentration of the minocycline hydrochloride  
30 in the samples is then measured by high pressure liquid chromatography and  
31 recorded. After a suitable wash-out period of two weeks, the bilayer dosage

1 forms were administered to the dogs and tested under the same conditions.  
2 The results of the study are presented in FIG. 7. The square symbols  
3 depicted in the graph correspond to the plasma concentration profile of drug  
4 generated by the single layer dosage form and the triangular symbols  
5 correspond to the plasma concentration profile of drug generated by the  
6 bilayer dosage form. The bilayer dosage form exhibits a multifold increase in  
7 drug bioavailability (as measured by the area under the curve; "AUC") and a  
8 more elevated plasma concentration compared to the single layer dosage  
9 form without the retention layer. The calculated AUC of the bilayer dosage  
10 form was  $119 \pm 26 \mu\text{g hr/ml}$  and the calculated AUC of the monolayer dosage  
11 forms was  $28.1 \pm 21 \mu\text{g hr/ml}$ .

#### 12 13 EXAMPLE 9

14 Dosage forms of the invention are prepared in accordance with the  
15 procedure of Example 7 having the following components and composition  
16 (all percentages are weight percent): The active agent layer (522 mg)  
17 contains 23% fexofenadine hydrochloride, 24.2% of Polyox WSR N-60K, 50%  
18 LHPC (low substituted hydroxypropylcellulose), 2% polyvinylpyrrolidone  
19 (PVPK 2932), 0.3% silicon dioxide (Aerosil 200) and 0.5% magnesium  
20 stearate. The highly-swellable layer (522 mg) contains 99% Polyox 303 and  
21 1% red ferric oxide. The first overcoat (33 mg) contains 80% Methocel A15LV  
22 Premium and 20% sorbitol. The banding material (21 mg) contains 69.9%  
23 Eudragit NE 40D (dry weight basis), 30% triacetin and 0.1% simethicone Q7-  
24 2587. The final overcoat (28 mg) contains 80% Methocel A15LV and 20%  
25 sorbitol. The release rate and cumulative release for representative dosage  
26 forms is presented in FIGs. 8A and 8B, respectively. The dosage forms  
27 exhibit a mean release rate of about 10.4 mg/hour and a  $T_{90}$ , time to deliver  
28 90% of the amount of active agent in the dosage form, of about 10.3 hours.

#### 29 30 EXAMPLE 10

31 Dosage forms are prepared in accordance with Examples 7 and 9

1 except that Polyox 301K is substituted for the Polyox WSR N-60K in the drug  
2 layer. The release rate and cumulative release of fexofenadine hydrochloride  
3 is presented in FIGs. 9A and 9B respectively. Representative dosage forms  
4 exhibit a mean release rate of about 7.4 mg/hour and a  $T_{90}$  of about 13.8  
5 hours.

#### 6 7 EXAMPLE 11

8 This example illustrates the identification and evaluation of  
9 compositions of the high-swelling layer. Formulation 1 was prepared by  
10 passing 25 grams of polyethylene oxide and 25 grams of cellulose fiber  
11 through a sieve with 4 wires per inch. The resulting mixture was tumble  
12 mixed in a V-blender for 10 minutes. The polyethylene oxide had a molecular  
13 weight of approximately 7 million grams per mole (Polyox 303). The cellulose  
14 fiber had an average fiber length of 110 microns and is supplied under the  
15 trade name SOLKA-FLOC 900FCC. The mixed powders were then  
16 transferred to a beaker where anhydrous ethyl alcohol formula SDA3A was  
17 added with stirring to form a uniform damp mass. The resulting damp mass  
18 was forced through a sieve with 20 wires per inch, producing elongated  
19 granules. The granules were then air dried overnight at ambient room  
20 conditions. The resulting dried granules were then forced with a spatula  
21 through the 20-mesh sieve to produce Granulation 1. A portion of  
22 Granulation 1 weighting 1.04 grams was filled into a punch and die set  
23 mounted on a Carver press. The tooling was caplet shaped, with major axis  
24 dimension of 0.85 inch (21.6mm) and a minor axis dimension of 0.3 inch (7.6  
25 mm). The caplet was compressed using a pressure head of 1.5 tons.

26 The swelling properties of the resulting caplet 1 were then evaluated in  
27 vitro. The caplet was placed in 900 ml of simulated gastric fluid therostated at  
28 37° C. The gastric fluid had a pH value of 1.2 and was prepared according to  
29 the formula, but without enzyme, as specified in the US Pharmacopeia  
30 23/National Formulary 18, page 2053. The compact was tested in this fluid  
31 using the paddle test apparatus described on page 1792 of the same

1 reference. The paddle speed was maintained at 212 revolutions per minute  
2 to simulate mechanical insult and abrasion in vivo in the environment of use.  
3 After 30 minutes of testing in these conditions, the caplet was removed. The  
4 dimension of the minor axis was measure using an optical inspection system  
5 (RAM Optical Instrumentation, Huntington Beach, California). The percent  
6 increase in the minor axis dimension was then calculated. The swollen caplet  
7 was then returned to the testing bath. After another 30 minutes in the bath  
8 under test conditions, the caplet was removed and the dimensions were again  
9 measured and the percent increase in the minor axis was again calculated.  
10 Each calculation was based o the dimension of minor axis at time zero, i.e.,  
11 7.6 mm. This process was continued hourly for the next four hours. The  
12 percent increase in minor axis dimension was plotted as a function of test  
13 time and the results are represented by the diamond-shaped symbols in  
14 FIG. 10.

15 Three other caplets having different compositions were prepared and  
16 tested according to the procedures described above. Formulation 2 consisted  
17 of 25 grams of Polyox 303, 12.5 grams of Solka-Floc 900FCC, and 12.5  
18 grams of sodium chloride. The dimensional changes of this caplet as a  
19 function of time are represented by hexagonal symbols in FIG. 10. The rate  
20 and extent of swelling of Formulation 1 and Formulation 2 were similar. Both  
21 increased in minor axis dimension by about 75% at a time of one hour and  
22 both swelled to about 140% by a time of 5 hours. Formulation 2 had a higher  
23 bulk density than Formulation 1 and flowed and filled die cavities more  
24 quickly, thus making it preferable for use in high speed tableting operations.

25 Formulation 3 consisted of 25 grams of Polyox 303 and 25 grams of  
26 sodium chloride. The results of swelling of the caplet formed of this  
27 formulation is illustrated in FIG. 10 by the open circular symbols. Swelling of  
28 this caplet at one hour was comparable to that of Formulations 1 and 2, but  
29 this caplet did not swell to the extent of the caplets formed from Formulations  
30 1 and 2 at the end of the five hour period. Formulation 4 consisted of 50  
31 grams of Polyox 303. Swelling behavior of the caplet of this granulation is

1 represented by the curve with the closed circles in FIG. 10. Formulation 4  
2 swelled more slowly and to a lesser extent than Formulations 1 and 2. The  
3 results demonstrate that the presence of cellulosic fibers increases the rate  
4 and extent of the swelling process over formulations that do not include the  
5 fibers. Also, the presence of the sodium chloride provides a granulation bulk  
6 density that is more suitable for high speed tableting processes than  
7 formulations without the sodium chloride.

8

9 *Sub a3*

10 The present invention is described and characterized by one or  
11 more of the following technical features and/or characteristics, either alone or  
12 in combination with one or more of the other features and characteristics: an  
13 active agent dosage form adapted for gastric retention comprising: (a) a first  
14 layer comprising a swellable, water-soluble polymer; (b) a second layer  
15 comprising a therapeutically-effective amount of an active agent, the second  
16 layer being laminated with the first layer at a common surface, and (c) at least  
17 one band of insoluble material circumscribing and binding together the first  
18 layer and the second layer, the first layer being adapted to swell in the  
19 stomach to facilitate retention of the dosage form in the stomach over a  
20 prolonged period of time, wherein the release of the active agent from the  
21 second layer is independent of the composition of the first layer and occurs  
22 over a prolonged period of time; a dosage form wherein the number average  
23 molecular weight of the water-soluble polymer is between about 100,000 and  
24 20,000,000 grams per mole; a dosage form wherein the water soluble  
25 polymer is polyethylene oxide, hydroxypropyl cellulose, hydroxypropyl methyl  
26 cellulose, hydroxyethyl cellulose, sodium carboxy methylcellulose, calcium  
27 carboxymethyl cellulose, methyl cellulose, polyacrylic acid, maltodextrin, pre-  
28 gelatinized starch, guar gum, sodium alginate, or polyvinyl alcohol; a dosage  
29 form wherein the second layer comprises a hydroattractant selected from low-  
30 substituted hydroxypropyl cellulose, microcrystalline cellulose, cross-linked  
31 sodium or calcium carboxymethyl cellulose, cellulose fiber, cross-linked  
polyvinyl pyrrolidone, cross-linked polyacrylic acid, cross-linked Amberlite

66227-6623463

1 resin, alginates, colloidal magnesium-aluminum silicate, corn starch granules,  
2 rice starch granules, potato starch granules and sodium carboxymethyl  
3 starch, and the first layer optionally comprises a hydroattractant selected from  
4 low-substituted hydroxypropyl cellulose, microcrystalline cellulose, cross-  
5 linked sodium or calcium carboxymethyl cellulose, cellulose fiber, cross-linked  
6 polyvinyl pyrrolidone, cross-linked polyacrylic acid, cross-linked Amberlite  
7 resin, alginates, colloidal magnesium-aluminum silicate, corn starch granules,  
8 rice starch granules, potato starch granules and sodium carboxymethyl  
9 starch; a dosage form wherein the first layer swells more rapidly and to a  
10 greater extent than does the second layer; a dosage form wherein the active  
11 agent is. an antiviral, antimicrobial, antidiabetic, antihyperglycemic,  
12 hypoglycemic, antidepressant, antiobesity or antifungal active agent; a  
13 dosage form wherein the weight percent of the water soluble polymer in the  
14 second layer is 5 to 99.99 weight percent and weight percent of the  
15 hydroattractant in the second layer is 0 to 60 weight percent; a dosage form  
16 wherein the prolonged time period is at least 3 hours; a dosage form wherein  
17 the prolonged time period is between about 6 to 12 hours; a dosage form  
18 wherein the first layer comprises polyethylene oxide having a number  
19 average molecular weight of at least 100,000 grams per mole; a dosage form  
20 wherein the active agent is acyclovir, ganciclovir, ritonavir, minocycline,  
21 cimetidine, ranitidine, captopril, methyl dopa, selegiline, minocycline,  
22 fexofenadine, metformin, bupropion, orlistat or a pharmaceutically acceptable  
23 salt thereof; a dosage form wherein the second layer comprises an active  
24 agent selected from the group consisting of acyclovir, ganciclovir, ritonavir,  
25 metformin, bupropion, orlistat and minocycline, and the second layer  
26 comprises a bioerodible polymer, a therapeutically effective amount of the  
27 active agent being delivered to the stomach of a subject over at least a 3 hour  
28 period; a method of treating a subject in need thereof with an active agent  
29 that comprises administering to the subject a multilayered dosage form  
30 adapted to be retained in the stomach over a prolonged period of time, the  
31 dosage form comprising a second layer adapted to swell in the stomach of

1 the subject and retain the dosage form in the stomach for a prolonged period  
2 of time, and a first layer adapted to deliver to the subject an active agent at a  
3 variable rate of delivery; a method which comprises administering one or  
4 more dosage forms to the subject in the fed state at the start of each dosing  
5 period; a method wherein the administration of the dosage form occurs within  
6 one hour of the subject consuming food; a dosage form comprising a gastric-  
7 emptying delaying agent; a dosage form wherein the gastric-emptying  
8 delaying agent is selected from anticholinergic agents, methylcellulose, guar  
9 gum, fats and fatty acids of 10-15 carbon atoms; a dosage form wherein the  
10 active agent comprises a liquid, active agent formulation; a dosage form  
11 wherein the liquid, active agent formulation is sorbed into porous particles; a  
12 dosage form wherein the porous particles are calcium hydrogen phosphate or  
13 magnesium aluminometasilicate; a dosage form comprising a pH regulating  
14 agent or a chelating agent; a dosage form wherein the liquid, active agent  
15 formulation comprises a pH regulating agent selected from organic and  
16 inorganic acids and bases, a dosage form wherein the liquid, active agent  
17 formulation comprises a chelating agent.

18 The above description has been given for ease of understanding only.  
19 No unnecessary limitations should be understood therefrom, as modifications  
20 will be obvious to those skilled in the art.